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Abstract 
 
 
Smoking and mental illness are leading contributors to mortality and morbidity in the U.S. 
They are also significantly associated with each other, as people with mental illness 
smoke at much higher rates compared to the general population. While it is known that 
people with mental illness have shorter life expectancies than people without, the extent 
to which this is associated with their increased smoking had previously been unknown. In 
Chapter 2, I use survival analysis and the National Health Interview Surveys 1997-2009 
mortality follow-up data to construct lifetables by smoking and mental health status. I find 
that at age 40, never smokers with SPD lose approximately 5.3 years of life expectancy 
compared to current smokers with SPD who lose 14.9. Thus smoking is a primary driver 
of differences in life expectancy by mental health status. 
In Chapter 3, I use simulation methods to adjust for recall error in national surveys and 
produce revised estimates of lifetime prevalence of major depression (MD) in the U.S. I 
develop a simple compartmental model of MD calibrated to data from the National Survey 
on Drug Use and Health (NSDUH). I show that over 40% of adults with lifetime MD 
underreport their histories of depression. After adjusting for recall error, 28.7% and 16.0% 
of women and men have lifetime MD compared to 15.6% and 9.5% when relying on self-
report.  
 xii 
 
In Chapter 4, I develop the first model to evaluate the joint impact of smoking and mental 
health in the U.S. I calibrate a system dynamics model of smoking and depression 
comorbidity to NSDUH data 2005-2015 and show that the smoking prevalence disparity 
by depressive status is projected to widen over time. From 2016 to 2050, women and 
men with MD are expected to become increasingly more likely to smoke compared to 
their never depressed counterparts. Adults with current MD represent 6.7% of the adult 
population, but more than 640,000 smoking-attributable deaths are projected to occur in 
this group. While the proportion of smoking-attributable deaths among adults with 
depression is projected to decrease with time, even by 2050 parity with those who have 
no history of MD would not be achieved.  
In Chapter 5, I evaluate the health gains associated with smoking cessation interventions 
that target patients with depression. I simulate the effects of widespread access to 
cessation treatment and increased utilization of mental health services among smokers 
with depression. Under a highly optimistic scenario that assumes all patients with 
depression receive cessation medication from their mental health professionals in 2018, 
less than 31,400 premature deaths would be avoided by 2050. This represents only about 
5% of the nearly 600,000 smoking-attributable deaths that are projected to occur among 
adults with depression during the same period. Increases in the level of mental health 
service utilization would offer some additional but marginal health gains. While cessation 
interventions in mental health settings would reduce the smoking disparity by depression 
status, the mortality benefits associated with doing so are modest and should be pursued 
alongside more aggressive tobacco control strategies.  
 xiii 
 
This dissertation advances knowledge about the impact of smoking and mental illness 
comorbidities on population health. It furthermore demonstrates the potential for systems 
science approaches to inform the epidemiology of behavioral health conditions, assess 
changes to tobacco use disparities over time, and evaluate the long-term effects of 
interventions.  
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Chapter 1 - Introduction 
 
 “The depression was burying me…I would smoke more to not be depressed, and 
then be more depressed because I was smoking. That was a vicious, vicious 
cycle.” – Rebecca, age 571 
 
Rebecca started smoking when she was a teenager, and was diagnosed with depression 
at age 33. She spent years feeling helpless to both her depression and her tobacco 
addiction, and finally found the motivation to quit smoking after she began losing her teeth. 
In the Centers for Disease Control and Prevention (CDC) Tips from Former Smokers 
campaign, she describes the cycle that kept her hostage during this time. Unfortunately, 
her experience is a common one for people with mental illness.  
According to the National Survey on Drug Use and Health, of the 44.7 million adults in 
the United States with any mental illness, 1 in 3 are past month smokers.2,3 For 
comparison, 1 in 5 adults with no mental illness smokes.4 Although people without mental 
illness have benefited from significant declines in smoking over time, comparable trends 
have not been observed for people with mental illness.5,6 Furthermore, an analysis using 
national cohort data showed that more recent birth cohorts of smokers have elevated 
psychiatric vulnerability, pointing to a shift in the smoking population, as it increasingly 
represents people with mental disorders.7 In the U.S., people with mental illness smoke 
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at higher rates, with greater intensity, and are less successful at quitting than people 
without mental illness.8-10 The likelihood of smoking among people with a mental disorder 
increases with the severity and with the number of other co-occurring psychiatric 
disorders.8,11 These tobacco use disparities translate into higher burdens of tobacco-
related disease and death for people with mental illness. More than half of all deaths 
among people with severe mental illness are due to cancer, heart disease, stroke, or 
other conditions caused by smoking.12 People with behavioral health conditions are 
especially vulnerable to tobacco addiction, and as a result face a disproportionate share 
of the debilitating health conditions associated with smoking.  
Why do people with mental illness smoke more? 
One of the most common explanations for the persistent tobacco use disparity by mental 
health status is referred to as the ‘self-medication hypothesis.’ This hypothesis reasons 
that people with psychiatric disorders smoke more because the nicotine alleviates 
symptoms of their mental illness, thereby reducing negative affect and improving their 
physiological functioning.13 Edward Khantzian proposed this hypothesis in 1985 as an 
explanation for widespread illicit drug use among people with psychiatric conditions.14 He 
later updated his theory to emphasize that “it is not so much a psychiatric condition that 
one self-medicates, but a wide range of subjective symptoms and states of distress that 
may or may not be associated with a psychiatric disorder.”14 However the self-medication 
hypothesis has become less accepted as a way of understanding nicotine addiction 
among people with mental illness with more recent research.15-19 
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Research indicates that continued cigarette smoking may not alleviate psychiatric 
symptoms per se, but rather alleviates symptoms of nicotine withdrawal (e.g. irritability).20 
People with mental illness may be more vulnerable to cravings and nicotine withdrawal 
when trying to quit,21 and also find the experience of smoking to be more rewarding than 
their mentally healthy counterparts.22,23 In tests of whether cigarette smoking improves 
mood, data has shown that it is ineffective at reducing depressive symptoms.24 It has 
been posited that because nicotine increases the rate at which medications metabolize, 
patients with schizophrenia may be smoking to alleviate the side effects of antipsychotic 
medications.15 Evidence that nicotine allays medication side effects is mixed and 
somewhat difficult to reconcile with the apparent absence of a simultaneous reduction in 
the beneficial effects of such drugs.15 Tests of cognition and attention behaviors among 
people with schizophrenia also indicated that nicotine is unlikely to produce the subjective 
additional benefits perceived by patients relative to mentally healthy people.25 If the self-
medication hypothesis holds, it follows that a reduction in smoking would lead to negative 
changes in mental health, which research has not demonstrated.26 In a National Institute 
of Mental Health report, experts concluded that “overreliance on the self-medication 
hypothesis...may result in inadequate attention to other potential explanations.”22 
Instead, a growing body of research has investigated the possibility of other causal links 
between tobacco smoking and poor mental health.22 Although it is difficult to ascertain 
causality based on observational data, a systematic review of longitudinal survey data 
demonstrates that depression and anxiety predict subsequent smoking and vice versa.27 
A 13-year prospective study of young women found that after adjusting for other mental 
health history and sociodemographic factors, baseline smoking predicted psychological 
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distress and depression at subsequent waves, and poor mental health at baseline 
predicted subsequent smoking.28 Critiques of the self-medication hypothesis also point to 
evidence that indicates quitting smoking reduces anxiety, stress, and depressive 
symptoms.29,30 A systematic review and meta-analysis of 26 tobacco cessation 
interventions found significant improvements to mental health following smoking 
cessation.20 Another study using propensity score matching methods corroborates this 
finding.31 Results from a Mendelian randomization analysis suggests that tobacco use 
could causally develop psychotic conditions: a gene variant related to smoking intensity 
was associated with schizophrenia in smokers but not never-smokers, though the study 
did not find similar results for depression.32  
Tobacco industry tactics may have contributed to higher smoking (or delayed reductions 
to smoking) in populations with mental illness. Tobacco companies have funded research 
and scientific meetings that promote the idea that nicotine is helpful to people with 
schizophrenia as a form of self-medication.33,34 Furthermore, the industry has a history of 
targeting people with mental illness as a base of consumers, typically as part of corporate 
social responsibility aims.35 Industry documents show that marketing efforts included 
distributing free cigarette samples to psychiatric hospitals, drug treatment facilities, and 
homeless shelters. Companies have also cultivated relationships with and provided 
grants to service organizations that primarily serve the homeless or people with mental 
illness. Media marketing campaigns emphasized the benefits of smoking for stress relief 
and relaxation.34,36  
Mental health professional norms likely have contributed to continued smoking among 
people with mental disorders. Historically, psychiatrists have been the least likely medical 
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specialty to address tobacco use in their patients, believing that they have other health 
problems that were more pressing or that quitting smoking would worsen their mental 
health.37-39 Staff in mental health facilities often perceive smoking to be a secondary 
concern for their patients, and view nicotine as having a therapeutic role in patient’s lives. 
Mental health professionals are sometimes under the impression that their patients do 
not want to quit,39 despite the fact that smokers with depression and other disorders are 
motivated to quit smoking40,41 and interventions have been shown to work for them.42,43 
At the same time, patients with severe mental illness do not view their mental health 
providers as avenues for cessation treatment, and report receiving little support or 
encouragement from them to quit.38 Early efforts to implement smoke-free policies in 
psychiatric facilities were initially met with protest from mental health organizations 
concerned about how such policies would disrupt patient care, but a growing number of 
facilities eventually became smoke-free without issue.33,44-48  
Shared underlying genetic and social vulnerability is an important and likely explanation 
for the co-occurrence of smoking with mental disorders.49 In studies of twins, genetic 
factors that have been linked to nicotine dependence also predisposed individuals to 
major depression.50 Numerous gene systems connected to smoking behaviors have been 
associated with psychiatric conditions, especially schizophrenia; this suggests that some 
genes can confer susceptibility to neuropsychiatric disorders.51,52 Beyond genetics, 
people with mental illness are more likely to live in poverty, be less educated, be 
unemployed, lack social support—all social and environmental characteristics that have 
independently been associated with tobacco addiction.53-55 Vulnerable populations are 
disproportionately affected by stress, discrimination, and homelessness, which are known 
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to be associated with substance use behaviors. This can have compounding effects, in 
which the interaction of low socioeconomic status with poor mental health leads to even 
worse smoking outcomes than when considered independently.55,56 
Systems science and models of smoking 
The dynamic nature of the relationship between poor mental health and tobacco 
addiction, and the potential for feedback mechanisms that reinforce both of these 
conditions simultaneously, makes their co-occurrence appropriate for the application of 
systems science methods. Systems science is a trans-disciplinary approach to the study 
of nonlinear, adaptive complex systems which emphasizes the inter-relatedness of 
components within a system and emergent effects generated that are larger than the sum 
of their individual parts. Systems science is no stranger to public health, as these methods 
have been used by researchers to develop computational models that improve knowledge 
about health disparities driven by feedback effects, how behaviors and contagions are 
spread through social networks, and dynamic interactions between humans and the 
environment.57-61  
In the field of tobacco control, system science approaches are increasingly valued and 
utilized by government agencies to facilitate decision-making and long-term planning.62-
65 Numerous simulation models have been developed by researchers to evaluate tobacco 
use behaviors and the policy interventions to address them.66-78 Such models have been 
used to estimate the impact of tobacco control on declines in smoking and on increasing 
life expectancy,79,80 the potential impact of e-cigarettes and other novel tobacco products 
on changes to smoking and smoking-related mortality,62,81-84 and the effects of peer 
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influences on the spread and clustering of smoking behavior.85-90 To my knowledge, very 
few have studied comorbid smokers, and models that consider smoking and comorbid 
illness have mainly examined tobacco addiction co-occurrence with infectious 
diseases.72,91 Although a systems dynamics model was previously employed to evaluate 
the effects of removing menthol cigarettes (which are primarily smoked by African-
Americans) from the cigarette market,92 existing simulation models of smoking generally 
have yet to consider marginalized populations.  
Public health decision-makers and tobacco regulators have demonstrated an 
appreciation for the use of systems science methods to monitor population health and 
evaluate large-scale interventions. At the same time, tobacco control leaders are directing 
attention to the unaddressed smoking disparity between populations with and without 
mental illness. This presents a unique public health and research opportunity. This 
dissertation advances knowledge of the population health effects of smoking and mental 
illness co-occurrence using system dynamics modeling methods. System dynamics 
models are mathematical models characterized by feedback loops (between smoking and 
poor mental health), time delays between events (smoking uptake) and their outcomes 
(disease and death), compartments of individuals (never, current, and former smokers) 
and the flows between them (initiation and cessation rates)— features that make them 
particularly well-suited for my research agenda.93  
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Overview of chapters 
Both smoking and mental illness independently contribute to premature death at the same 
time that their co-occurrence is driven by known and unknown etiological processes. But 
to what extent do populations with mental illness experience unequal health outcomes 
with respect to smoking? What are the consequences of smoking and mental illness 
comorbidity at the population level? How might they be addressed? These are questions 
I explore.  
Previous research has established that people with mental disorders live shorter lives and 
have greater mortality risk than those without mental disorders.94 However much of the 
existing literature on premature mortality for people with mental disorders fails to 
disentangle the contributions of smoking and serious mental illness to decreased life 
expectancy. How much of their reduced life expectancy is due to their mental illness or to 
their significantly higher smoking rates? In Chapter 2, I use survival analysis to generate 
lifetables and calculate life expectancy by smoking status and mental health status. I also 
estimate the smoking-attributable fraction of all deaths among people with serious mental 
illness. This is the first study to quantify the contribution of smoking to reduced life 
expectancy among people with serious mental illness. 
In Chapter 3, I focus on people with major depression. Major depression is a commonly 
occurring mental disorder with a well-documented relationship to smoking behavior.27,95 
Screening for depression in the general population comes with challenges. Many people 
fail to accurately recall their past histories of mental health including depressive 
symptoms.96,97 I develop a system dynamics model of major depressive episodes, 
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combining cross-sectional survey and cohort study data to adjust for recall error and 
estimate the lifetime burden of depression in the U.S. This model of major depression 
provides the foundation for a larger model that evaluates its concurrence with smoking. 
In Chapter 4, I describe the first joint model of smoking and mental illness comorbidity in 
the U.S. I evaluate both smoking and depression in the adult population, projecting future 
population health outcomes from 2016 through the year 2050. This modeling approach is 
informed by longitudinal research on the effects of smoking and depression on each 
other, and estimates their interaction effects. It can evaluate the smoking disparity by 
mental health status, and changes in the tobacco and mortality burden for people with 
depression over time.  
Next, I use the comorbidity model from Chapter 4 to understand how unequal health 
outcomes by depression status can be addressed through smoking cessation 
interventions that target patients with depression. Chapter 5 offers a glimpse into a 
hopeful future where cessation treatment is widely available, where mental health 
professionals fulfill their obligation to help patients quit, and where mental health care is 
more accessible to the people who need it.  
Finally, I conclude by reflecting on the contributions that the collection of studies makes 
to the existing literature. I consider future research and policy directions prompted by this 
body of work and offer new questions worthy of inquiry. 
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Chapter 2 - Smoking and the reduced life expectancy of individuals with serious 
mental illness 
 
Background 
The annual risk of death for individuals with mental disorders is more than twice that of 
the general population.1 Not only do those with mental illness lose on average 10 years 
of potential life,1 quality of life is reduced by the major contribution of these disorders to 
overall disability.2 The impact of psychological distress on health is perhaps most 
exemplified by the more than 40,000 deaths due to suicide each year.3 However a large 
proportion of deaths among those with mental disorders are ultimately due to chronic 
diseases such as heart disease, cancer, and stroke.4 This may be due to social 
deprivation, risks associated with antipsychotic medications, and in particular, harmful 
health behaviors such as smoking.4-9 
Though 19% of adults have some form of mental illness, previous estimates indicate that 
they account for nearly 40% of all cigarettes smoked in the U.S.10 This figure could now 
be larger as people with mental illness make up an increasing proportion of the country’s 
remaining smokers.11 Prevalence of cigarette smoking varies by diagnosis; it can be as 
high as 46% among those with bipolar disorder and 59% among those who have 
schizophrenia.12 On average, smoking rates are 70% higher among adults with any 
mental illness compared to the general population.13 This translates into even greater 
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mortality risk for populations with psychiatric disorders. A previous study found that half 
of total deaths among those with schizophrenia, bipolar disorder, and depression are due 
to diseases linked to smoking.14   
While tobacco use is a contributor to early death among those with psychiatric disorders, 
the extent to which smoking affects excess mortality, independent of mental illness, is 
unknown. Several studies examining mortality comparing populations with and without 
mental disorders adjust for confounding due to smoking. However these studies are 
restricted to veterans,15,16 California-based or non-U.S. patient populations,4,14 and 
middle-aged or elderly individuals.17-20 These estimates cannot be generalized to the 
broader U.S. population, and often exclude the non-patient population, who do not seek 
or are unable to access mental health care.  
I use nationally-representative data to estimate (1) the relative rates of death for smoking 
and serious psychological distress adjusting for relevant covariates, and (2) the impact of 
smoking on all-cause mortality and life expectancy among persons with serious 
psychological distress (SPD) in the U.S. 
Methods 
Data source 
The National Health Interview Survey (NHIS) surveys the civilian, non-institutionalized 
U.S. population. Beginning in 1997, NHIS identified adults with serious psychological 
distress (SPD) according to the Kessler-6 (K-6) non-specific psychological distress scale. 
The survey asks respondents about the frequency over the past month with which they 
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have felt (1) nervous, (2) hopeless, (3) restless or fidgety, (4) so sad or depressed that 
nothing could cheer the respondent up, (5) that everything is an effort, and (6) worthless. 
Each item is scored 0-4 based on the response “none of the time”, “a little of the time”, 
“some of the time”, “most of the time”, or “all of the time.” Individuals with scores of 13 or 
greater are considered to have SPD. This measure is a validated tool for screening 
serious mental illness in the general population.21,22  
Current smoking is defined as having smoked at least 100 cigarettes in one’s lifetime, 
and currently smoking every day or some days.23,24 Former smokers have smoked at 
least 100 cigarettes but do not currently smoke. Nondrinkers are those who report zero 
alcohol use in the past year. Non-heavy drinkers report drinking in the past year, but no 
heavy drinking, where heavy drinking is defined as 5 or more drinks on one occasion. 
Individuals who have had any heavy drinking episodes in the past year are divided 
according to frequency of heavy drinking occasions: less than 3 heavy drinking days per 
week, and 3 or more heavy drinking days per week. Alcohol use categories were based 
on a study that found frequency of heavy drinking to better capture mortality risk 
compared to average daily consumption.25  
Mortality follow-up data are available for a subsample of NHIS participants linked to death 
certificate information from the National Death Index from the date of survey through 
2011.26  Because NHIS only collects mortality data upon follow-up, all behavioral and 
demographic data are based on time of survey. The data thus do not allow for analysis of 
changing health status or behaviors over time. NHIS data for the years 1997-2009 were 
pooled to generate a final analytical sample of 328,110 individuals. I adhered to 
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recommended procedures from the National Center for Health Statistics to adjust pooled 
sampling weights for the mortality follow-up sample.26  
Analysis 
I used Cox regression models to estimate mortality hazard ratios stratified by 10-year age 
groups. Individuals age<25 were excluded from analyses because many people below 
this age have not yet attained their highest level of education. Survival models related 
time to death in years, and adjusted for smoking status, gender, race/ethnicity, education, 
age at baseline (continuous variable), marital status, and alcohol consumption. I also 
estimated mortality hazard ratios specifically for the population with SPD, stratified by 
gender, and adjusting for the aforementioned variables and year of birth.  
The proportional hazards assumption was assessed for each covariate through 
interaction terms with log of time in years. As baseline mortality rates for lifetable 
construction are not available by race/ethnicity or alcohol consumption, I did not further 
stratify the NHIS cohort beyond age group and gender. Cox models did not include time-
dependent variables for smoking, drinking, and SPD status since these are only available 
at baseline. Given the known correlation between mental illness and tobacco use, I tested 
for interactions between smoking status and SPD.  
For comparison, I conducted similar survival analyses using national mortality follow-up 
data for other measures of mental illness, such as NHIS 2007 data for bipolar disorder 
and schizophrenia, and National Health and Nutrition Examination Survey (NHANES) 
data for anxiety disorder and depression. In general, small sample sizes resulted in very 
wide confidence intervals for the main coefficients of interest, and precluded lifetable 
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construction. Select results for the NHANES measure of depression are included at the 
end of this chapter (Appendix). 
Smoking-attributable fraction 
Mortality hazard ratios for current and former smoking were used to determine the 
smoking-attributable fraction (SAF) of preventable deaths among those with SPD. The 
calculation followed the CDC approach27:   
SAF =  
pcs(RRcs –  1)  +  pfs(RRfs –  1)
pcs(RRcs –  1)  +  pfs(RRfs –  1)  +  1
 
where pcs is the prevalence of current smoking in the population of interest, pfs is the 
prevalence of former smoking, RRcs is the relative risk of death for current smokers with 
SPD, and RRfs is the relative risk of death for former smokers with SPD compared to 
never smokers with SPD.  
Life expectancy 
To estimate the impact of smoking and mental illness comorbidity on life expectancy, I 
developed lifetables by gender according to smoking and SPD status. Lifetables were 
constructed according to the Human Mortality Database (HMD) protocol.28 I used the 
Cancer Intervention and Surveillance Modeling Network (CISNET) unadjusted never-
smoker mortality rates as baseline rates, and assume these approximate the rates in 
never smokers without mental illness. The CISNET data have been used in the 
development of multiple validated models of smoking, mortality and lung cancer.29-31 
Baseline death rates were adjusted by applying the estimated age group-specific mortality 
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hazard ratios for SPD, current smoking, and former smoking. I report results based on 
the 2009 never-smoker death rates; results using the 1997-2008 CISNET death rates are 
available upon request. 
Results 
Table 2-1 presents characteristics of the study population at baseline according to SPD 
status. Persons with SPD comprise 3.1% of the population. From 1997 to 2011, 38,266 
of all participants (9.5%) died at follow-up. A larger percentage of individuals with SPD 
died (14.2%) than did individuals without SPD (8.3%). Average follow-up time was 8.2 
years. Mean age was 49.5 years and 49.8 years for the SPD and no-SPD samples 
respectively. Participants with SPD were significantly more likely to be smokers, less likely 
to have quit, more male, more likely to be black or Hispanic, less educated, less likely to 
be married, and more likely to be divorced or separated compared to those without SPD.  
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Table 2-1. Baseline sample characteristics by SPD status, NHIS 1997-2009 
 No SPD SPD p-value 
Avg years of follow-up (sd) 8.19 (3.84) 7.85 (3.94)  
Deaths (%) 35117 (8.3) 2013 (14.2) <0.001 
Male (%) 136741 (52.2) 3760 (41.0) <0.001 
Smoking status (%)    
Never smoker 169934 (48.0) 4369 (28.2) <0.001 
Current smoker 66036 (23.6) 4798 (48.1) <0.001 
Former smoker 74040 (28.4) 2335 (23.7) <0.001 
Education (%)    
High school or less 147443 (41.3) 7673 (62.9) <0.001 
Some college 83841 (28.8) 2781 (27.1) <0.001 
College grad 78471 (29.8) 1031 (10.0) <0.001 
Race/ethnicity (%)    
Hispanic 49433 (9.6) 2359 (11.7) <0.001 
White (Non-Hispanic) 204579 (77.1) 6870 (71.6) <0.001 
Black (Non-Hispanic) 43038 (9.3) 1813 (12.0) <0.001 
Other (Non-Hispanic) 14158 ( 4.0) 514 ( 4.7) 0.786 
Age group (%)    
25-34 66614 (21.7) 2001 (19.0) <0.001 
35-44 70584 (24.5) 2738 (25.7) 0.074 
45-54 61282 (22.3) 2992 (27.4) <0.001 
55-64 45524 (15.1) 1926 (16.1) <0.001 
65-74 35341 (9.4) 969 (6.4) <0.001 
75-84 24650 (5.6) 708 (4.1) <0.001 
85+ 7556 (1.4) 229 (1.3) 0.966 
Birth cohort (%)    
1912-1929 37844 (8.0) 1107 (6.1) <0.001 
1930-1939 34433 (9.3) 1040 (6.9) <0.001 
1940-1949 48180 (15.7) 2070 (16.7) <0.001 
1950-1959 64679 (23.2) 3022 (27.7) <0.001 
1960-1969 70521 (24.3) 2637 (24.7) 0.765 
1970-1984 55894 (19.5) 1687 (17.9) <0.001 
Marital status (%)    
Never married 47559 (11.4) 2012 (14.5) <0.001 
Currently married 161494 (65.0) 3868 (45.6) <0.001 
Cohabiting 13276 (5.8) 622 (8.3) <0.001 
Divorced or separated 54032 (12.1) 3572 (24.1) <0.001 
Widowed 34435 (5.7) 1454 (7.5) <0.001 
Current drinking status (%)    
Nondrinker  50433 (20.3)   2957 (35.1)  <0.001 
Non-heavy drinker 128795 (55.5) 3462 (40.4) <0.001 
Heavy drinker, <3 times per week 51781 (23.0) 1701 (21.0) <0.001 
Heavy drinker, 3+ times per week 2814 (1.2) 294 (3.5) <0.001 
    
No. of observations 311551 11563  
(%) represent weighted proportions; SPD = serious psychological distress;  
Excludes individuals less than 25 years of age. 
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Table 2-2 and Table 2-3 present all-cause mortality hazard ratios by gender and age 
group adjusted for demographic and behavioral risk factors. Compared to those with at 
least a college degree, having a high school education or less significantly increased risk 
for death across all age groups except for those ages 85+. The hazard ratio was also 
higher for those with some college education, though this was not always significant for 
females. Risk of death was significantly greater for those who never married or who were 
divorced or separated compared to married individuals across most age groups. Relative 
to whites, black participants generally had higher mortality risk while Hispanic individuals 
had lower risk. Compared to non-drinkers, being a non-heavy drinker significantly 
reduced risk in most models. The effects of heavy drinking less than three times per week 
appeared to significantly reduce risk for some age groups, though results for more 
frequent heavy drinking were mixed and generally not statistically significant. My mixed 
results regarding heavy drinking could be explained by co-occurrence with smoking. 
When smoking variables were omitted in separate analyses, I noted that frequent heavy 
drinking increased mortality risk, though not significantly for most age groups. 
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Table 2-2. All-cause mortality hazard ratios by age group – Males 
Age group 25-34 35-44 45-54 55-64 65-74 75-84 85+ 
Current smoker 1.811*** 1.617*** 2.257*** 2.758*** 2.717*** 2.077*** 1.334 
  (1.377 - 2.382) (1.352 - 1.935) (1.942 - 2.623) (2.383 - 3.191) (2.400 - 3.077) (1.781 - 2.422) (0.932 - 1.911) 
Former smoker 1.458** 1.081 1.191** 1.438*** 1.487*** 1.311*** 1.216*** 
  (1.010 - 2.103) (0.851 - 1.374) (1.017 - 1.393) (1.252 - 1.651) (1.335 - 1.655) (1.205 - 1.426) (1.059 - 1.396) 
SPD 1.703* 2.101*** 1.768*** 1.483*** 2.098*** 1.489*** 1.783** 
  (0.960 - 3.021) (1.570 - 2.811) (1.408 - 2.219) (1.202 - 1.831) (1.698 - 2.592) (1.155 - 1.919) (1.108 - 2.871) 
Age 1.101*** 1.119*** 1.072*** 1.093*** 1.114*** 1.107*** 
 
  (1.054 - 1.151) (1.088 - 1.150) (1.052 - 1.094) (1.074 - 1.112) (1.098 - 1.130) (1.092 - 1.121) 
 
High school or less 2.166*** 1.961*** 1.714*** 1.741*** 1.347*** 1.231*** 1.151* 
  (1.480 - 3.170) (1.553 - 2.476) (1.454 - 2.020) (1.504 - 2.014) (1.211 - 1.497) (1.116 - 1.358) (0.982 - 1.350) 
Some college 1.846*** 1.658*** 1.416*** 1.407*** 1.230*** 1.049 1.059 
  (1.240 - 2.750) (1.305 - 2.107) (1.192 - 1.683) (1.199 - 1.651) (1.072 - 1.412) (0.934 - 1.179) (0.867 - 1.294) 
Hispanic 1.154 1.084 1.067 0.812*** 0.821*** 0.671*** 0.749* 
  (0.810 - 1.646) (0.858 - 1.368) (0.884 - 1.289) (0.695 - 0.950) (0.711 - 0.947) (0.568 - 0.793) (0.561 - 1.001) 
Black, NH 1.489** 1.381*** 1.486*** 1.265*** 1.206*** 0.906 0.626*** 
  (1.069 - 2.074) (1.104 - 1.727) (1.260 - 1.753) (1.100 - 1.455) (1.083 - 1.344) (0.778 - 1.054) (0.471 - 0.832) 
Other race, NH 1.022 1.337 1.022 1.196 0.689*** 0.730** 0.790 
  (0.540 - 1.935) (0.912 - 1.962) (0.755 - 1.384) (0.953 - 1.502) (0.528 - 0.899) (0.541 - 0.984) (0.547 - 1.141) 
Never married 1.678*** 2.052*** 1.907*** 1.759*** 1.449*** 1.148 1.139 
  (1.255 - 2.244) (1.695 - 2.485) (1.629 - 2.232) (1.474 - 2.099) (1.256 - 1.671) (0.958 - 1.376) (0.804 - 1.613) 
Cohabiting 0.832 1.344* 1.214 1.191 0.824 1.109 0.177* 
  (0.552 - 1.253) (0.985 - 1.834) (0.905 - 1.628) (0.919 - 1.544) (0.624 - 1.087) (0.799 - 1.540) (0.026 - 1.192) 
Divorced/separated 1.273 1.652*** 1.710*** 1.444*** 1.349*** 1.159** 0.977 
  (0.841 - 1.929) (1.368 - 1.995) (1.501 - 1.948) (1.282 - 1.626) (1.226 - 1.484) (1.016 - 1.321) (0.688 - 1.389) 
Widowed†  1.116 2.035*** 1.842*** 1.192*** 1.079* 1.240*** 
   (0.428 - 2.910) (1.421 - 2.915) (1.500 - 2.262) (1.073 - 1.326) (0.989 - 1.176) (1.099 - 1.400) 
Non-heavy drinker 0.882 0.658*** 0.605*** 0.594*** 0.736*** 0.719*** 0.807*** 
  (0.587 - 1.325) (0.533 - 0.812) (0.529 - 0.691) (0.528 - 0.669) (0.677 - 0.799) (0.661 - 0.781) (0.708 - 0.920) 
Heavy drinker, <3 
times per week 
  0.742 0.699*** 0.615*** 0.709*** 0.684*** 0.804** 0.763 
(0.501 - 1.099) (0.567 - 0.862) (0.531 - 0.712) (0.621 - 0.809) (0.594 - 0.788) (0.673 - 0.961) (0.502 - 1.161) 
Heavy drinker, 3+ 
times per week  
1.086 1.041 1.146 0.968 0.977 1.158 1.021 
(0.546 - 2.160) (0.719 - 1.507) (0.879 - 1.493) (0.751 - 1.249) (0.774 - 1.234) (0.827 - 1.622) (0.450 - 2.320) 
No. of observations 24841 27763 24484 17648 12183 7161 1708 
*** p<0.01, ** p<0.05, * p<0.1; 95% CI presented below hazard ratios; Reference groups omitted from table: never smoker, college graduate, non-
Hispanic, white NH, married, nondrinker; NH = non-Hispanic; Ages 85+ are top-coded; †Widowed coefficient for ages 25-34 could not be 
estimated due to collinearity with the mortality variable.  
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Table 2-3. All-cause mortality hazard ratios by age group – Females 
Age group 25-34 35-44 45-54 55-64 65-74 75-84 85+ 
Current smoker 1.425** 3.199*** 2.484*** 2.845*** 2.782*** 2.269*** 1.332** 
  (1.027 - 1.979) (2.578 - 3.969) (2.109 - 2.926) (2.453 - 3.300) (2.485 - 3.115) (1.996 - 2.579) (1.018 - 1.743) 
Former smoker 0.920 1.304* 1.425*** 1.736*** 1.655*** 1.580*** 1.165** 
  (0.571 - 1.482) (0.955 - 1.780) (1.175 - 1.727) (1.499 - 2.011) (1.495 - 1.831) (1.459 - 1.711) (1.024 - 1.327) 
SPD 3.584*** 1.904*** 2.148*** 1.677*** 1.693*** 1.587*** 1.335 
  (2.287 - 5.615) (1.398 - 2.594) (1.687 - 2.735) (1.327 - 2.119) (1.335 - 2.149) (1.260 - 1.999) (0.931 - 1.915) 
Age 1.073*** 1.092*** 1.108*** 1.073*** 1.118*** 1.104***   
  (1.018 - 1.130) (1.052 - 1.134) (1.080 - 1.137) (1.051 - 1.095) (1.100 - 1.135) (1.088 - 1.120)   
High school or less 2.586*** 1.395** 1.567*** 1.493*** 1.315*** 1.226*** 0.999 
  (1.639 - 4.081) (1.062 - 1.834) (1.264 - 1.943) (1.239 - 1.799) (1.136 - 1.522) (1.078 - 1.394) (0.835 - 1.195) 
Some college 2.134*** 1.157 1.395*** 1.215** 1.088 1.074 0.852 
  (1.320 - 3.450) (0.872 - 1.534) (1.118 - 1.741) (1.003 - 1.470) (0.925 - 1.279) (0.939 - 1.230) (0.687 - 1.057) 
Hispanic 0.685* 1.148 0.893 0.864 0.772*** 0.831* 0.730 
  (0.441 - 1.064) (0.859 - 1.535) (0.679 - 1.174) (0.663 - 1.126) (0.638 - 0.934) (0.679 - 1.018) (0.493 - 1.081) 
Black, NH 1.138 1.528*** 1.414*** 1.424*** 1.061 0.946 0.828* 
  (0.716 - 1.808) (1.209 - 1.932) (1.151 - 1.738) (1.210 - 1.677) (0.935 - 1.204) (0.835 - 1.072) (0.664 - 1.034) 
Other race, NH 1.017 0.632 0.954 0.858 0.837 0.722* 0.802 
  (0.476 - 2.172) (0.317 - 1.259) (0.623 - 1.461) (0.580 - 1.269) (0.609 - 1.150) (0.519 - 1.004) (0.452 - 1.423) 
Never married 1.742*** 1.392** 1.539*** 1.655*** 1.287** 1.615*** 1.052 
  (1.208 - 2.512) (1.062 - 1.824) (1.216 - 1.947) (1.335 - 2.050) (1.045 - 1.583) (1.333 - 1.957) (0.744 - 1.486) 
Cohabiting 0.600 1.087 1.143 0.783 0.946 0.642 0.796 
  (0.311 - 1.157) (0.748 - 1.581) (0.838 - 1.559) (0.499 - 1.228) (0.588 - 1.522) (0.322 - 1.279) (0.325 - 1.947) 
Divorced/separated 1.164 1.239* 1.296*** 1.367*** 1.160** 1.211** 1.121 
  (0.782 - 1.733) (0.979 - 1.568) (1.097 - 1.531) (1.182 - 1.582) (1.010 - 1.333) (1.037 - 1.415) (0.800 - 1.571) 
Widowed 1.875 1.586 1.556*** 1.546*** 1.287*** 1.188*** 1.065 
  (0.456 - 7.708) (0.858 - 2.930) (1.173 - 2.063) (1.307 - 1.829) (1.169 - 1.418) (1.076 - 1.310) (0.869 - 1.305) 
Non-heavy drinker 0.591*** 0.658*** 0.597*** 0.569*** 0.584*** 0.731*** 0.757*** 
  (0.399 - 0.875) (0.524 - 0.826) (0.507 - 0.703) (0.502 - 0.645) (0.533 - 0.641) (0.679 - 0.788) (0.671 - 0.853) 
Heavy drinker, <3 
times per week 
0.641** 0.579*** 0.702*** 0.510*** 0.606*** 0.946 0.592 
(0.422 - 0.972) (0.418 - 0.804) (0.555 - 0.889) (0.393 - 0.662) (0.460 - 0.799) (0.661 - 1.353) (0.300 - 1.167) 
Heavy drinker, 3+ 
times per week 
0.306 0.996 0.944 1.118 1.968** 0.647 0.495*** 
(0.040 - 2.359) (0.468 - 2.118) (0.490 - 1.818) (0.508 - 2.459) (1.172 - 3.305) (0.252 - 1.664) (0.333 - 0.735) 
No. of observations 27408 29574 25698 17906 12709 8705 2485 
*** p<0.01, ** p<0.05, * p<0.1; 95% CI presented below hazard ratios; Reference groups omitted from table: never smoker, college graduate, non-
Hispanic, white NH, married, nondrinker; NH = non-Hispanic; Ages 85+ are top-coded; †Widowed coefficient for ages 25-34 could not be 
estimated due to collinearity with the mortality variable.  
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Hazard ratios were as expected for my variables of interest, with current smoking, former 
smoking, and SPD significantly increasing risk of death for males and females across 
most age groups. Mortality risk for current smoking increased by age group and was 
highest for males ages 55-64 and females ages 35-44 and 55-64. Risk for death among 
former smokers was also greatest among middle aged groups, declining for older age 
groups. 
In earlier runs, interaction terms between former smoking and SPD were found to be 
insignificant, and so were left out of the final models. The interaction term between current 
smoking and SPD was significant only for males ages 85+. The large male 85+ interaction 
term and its low precision translated into inflated mortality estimates. In favor of more 
conservative and precise hazard ratios, I omitted this term from the final model presented 
here and used for lifetable construction.  
The proportional hazards assumption was satisfied for most covariates included in the 
age-stratified models at the p<0.05 level, which suggests that the relative hazard is 
constant over time –a requirement for Cox models. I ran models stratified by the remaining 
covariates, and found that this did not noticeably affect estimates for my main variables 
of interest: current smoking, former smoking, or SPD.  
Table 2-4 shows estimated mortality ratios among persons with SPD by gender. Current 
smoking substantially increases risk of death for both males and females – approximately 
doubling the hazard relative to persons with SPD who have never smoked. Former 
smoking also increases the relative hazard rates, but was only statistically significant for 
 28 
 
females. As anticipated, mortality hazard ratios were considerably greater for those who 
have never married relative to married individuals, and Hispanic individuals had 
significantly reduced risk relative to non-Hispanic whites. All covariates in these models 
satisfied the proportional hazards assumption based on non-significance of time-
interaction terms. 
Table 2-4. All-cause mortality hazard ratios – SPD population 
 SPD population   
 Males Females 
Current smoker 2.093*** 1.887*** 
  (1.492 - 2.938) (1.513 - 2.354) 
Former smoker 1.212 1.367*** 
  (0.891 - 1.650) (1.091 - 1.713) 
Age 1.057*** 1.078*** 
  (1.025 - 1.091) (1.045 - 1.113) 
High school or less 1.343* 1.688** 
  (0.967 - 1.866) (1.117 - 2.550) 
Some college 1.187 1.309 
  (0.826 - 1.706) (0.851 - 2.013) 
Hispanic 0.679** 0.581*** 
  (0.503 - 0.916) (0.413 - 0.817) 
Black, NH 0.898 1.032 
  (0.652 - 1.237) (0.829 - 1.286) 
Other race, NH 0.594 0.558** 
  (0.314 - 1.123) (0.341 - 0.914) 
Never married 1.839*** 1.432** 
  (1.381 - 2.449) (1.022 - 2.007) 
Cohabiting 0.823 0.723 
  (0.483 - 1.400) (0.409 - 1.280) 
Divorced/separated 1.279** 1.011 
  (1.021 - 1.601) (0.789 - 1.297) 
Widowed 1.063 1.162 
 (0.764 - 1.479) (0.923 - 1.463) 
Non-heavy drinker 0.925 0.660*** 
  (0.736 - 1.163) (0.539 - 0.807) 
Heavy drinker, <3 times per week 0.965 0.844 
  (0.729 - 1.276) (0.622 - 1.146) 
Heavy drinker, 3+ times per week 1.466* 1.038 
  (0.963 - 2.230) (0.575 - 1.872) 
Year of birth 0.970** 1.002 
  (0.942 - 0.999) (0.971 - 1.034) 
   
No. of observations 3045 5269 
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Mortality hazard ratios were applied to estimate the smoking-attributable fraction of 
deaths among persons with SPD. This calculation was based on 46.2% smoking 
prevalence for SPD males (95% CI: 44.3%-48.1%) and 40.8% for females (95% CI: 
39.5%-42.2%), and 25.9% former smoking prevalence among males (95% CI: 24.2%-
27.6%) and 18.5% among females (95% CI: 17.3%-19.7%). Using confidence interval 
limits for both hazard ratios and prevalence estimates, the smoking attributable fraction 
ranged from 16%-53% among males and 18%-42% among females. Based on point 
estimates, approximately 36% and 30% of all deaths among males and females with SPD 
are due to smoking. For comparison, 26% of all deaths among people without SPD are 
smoking-attributable. 
Figure 2-1 presents years of potential life lost at age 40 compared to never smokers 
without SPD. Confidence bands represent reduced life expectancy using the 95% 
confidence intervals for each hazard ratio applied to baseline never-smoker death rates. 
Results at other ages are available upon request.  
Smoking with SPD costs individuals 14.9 years of life expectancy (average across males 
and females) compared to never smoking and not having SPD. For never smokers, 
having SPD reduces life expectancy by approximately 5.3 years. Thus, smoking accounts 
for nearly two-thirds of the overall difference in life expectancy between smokers with 
SPD and never smokers without SPD.  
Among individuals with SPD, being a current smoker reduces life expectancy by 
approximately 9.55 years compared to not smoking, and the difference in life expectancy 
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is maintained even when evaluating across confidence intervals. Those with SPD who 
have quit smoking have 5.75 more years of life compared to those who are current 
smokers. However confidence bands overlap for former and current smokers with SPD.  
Figure 2-1. Life expectancy reduction at age 40 by smoking and SPD status 
 
SPD = serious psychological distress; Estimates represent the difference in life 
expectancy between each group and never smokers without SPD; Life expectancy in 
never smokers without SPD is 41.6 years for men and 43.7 for women at age 40; 
Confidence bars represent estimates using the lowest and highest hazard ratio 
estimates (95% CI) applied to the reference group’s mortality rates. 
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Discussion 
To my knowledge, this is the first study to quantify the specific contribution of smoking to 
reduced life expectancy among persons with serious mental illness. My findings that SPD 
and smoking both independently reduce life expectancy corroborate previous 
research.1,32 However, I show that the difference in life expectancy between current 
smokers with SPD and never smokers without SPD is primarily due to smoking, which 
contributes to nearly two-thirds of the life years lost. I also find that one-third of all deaths 
among persons with SPD can be attributed to smoking.  
The analyses show the clear benefit to quitting smoking regardless of one’s mental health 
status. Former smokers with SPD have roughly 5 years of additional life compared to 
current smokers. However, the impact of serious mental illness on early death among 
former smokers is still strong, as their life expectancy is similar to that of current smokers 
who do not have SPD. Other results are generally consistent with existing literature on 
the effects of other demographic and behavioral risk factors for mortality, including 
research on the protective benefits of moderate drinking.33 
This study is strengthened by its use of nationally representative data and the most 
historically comprehensive mental health measure available in the U.S., as annual 
screening for SPD among adults began as early as 1997. Although non-specific 
psychological distress is not a diagnostic measure, it is a scale that significantly predicts 
serious psychiatric disorders in the general population.21,22 Furthermore, in separate 
analyses using the National Health and Nutrition Examination Survey (NHANES) and the 
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Patient Health Questionnaire (PHQ-9), a validated screening tool for clinical depression, 
I found smoking relative risks estimates consistent with those reported here (Appendix).  
Screening for SPD in the general population also captures individuals who are not 
receiving treatment. Thus my study has the advantage of being generalizable to the non-
patient population. However, NHIS does not survey homeless, military, incarcerated, or 
institutionalized groups known to have higher prevalence of smoking and mental 
disorders.34-38 Thus my analyses might underestimate the true impact of smoking and 
mental illness on mortality due to the exclusion of these groups, particularly those in 
psychiatric institutions.  
My estimations of the contribution of smoking to the excess mortality of persons with SPD 
may be conservative. This is because I use a general estimate of mortality risk for never 
smokers, one that inherently includes never smokers with SPD, as a baseline rate. Thus 
I might be underestimating the magnitude of differences in life expectancy. Moreover, I 
have not adjusted for the fact that persons with SPD smoke more cigarettes per day than 
do smokers without SPD.12,39 Higher daily cigarette consumption likely contributes to even 
greater mortality risk, potentially exacerbating the effects. 
My study is limited by the lack of data on mental health and smoking status for individuals 
over time. Health and behavioral data on NHIS respondents are collected at baseline and 
do not reflect their status upon follow-up. Unfortunately this is the nature of cross-
sectional national health surveys, which at most collect longitudinal mortality data for a 
subsample. Other longitudinal data sources with more comprehensive information may 
be able to address this issue, but are generally not representative of the U.S. population. 
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Previous studies have reported on the excess mortality among those with mental illness 
in other countries. A global meta-analysis estimated roughly a decade of potential life lost 
for individuals with mental disorders;1 This study suggests that much of this life 
expectancy reduction may be due to smoking. The finding that ~33% of deaths among 
persons with SPD are attributed to smoking is similar to estimates reported for UK patients 
with mental disorders.40 Researchers there have also shown that smoking among those 
patients contributes to substantial economic costs and total years of life lost at the 
population level.40 The work further examines differences in life expectancy at the 
individual level by age, gender, and smoking and mental health status.  
There may be considerable variation in life expectancy and smoking attributable mortality 
by type of mental disorder, and level of disease severity. Future research should examine 
the effect of smoking on mortality for specific psychiatric disorders. Research could further 
parse out mortality among individuals with mental illness by cause of death. Though much 
of the mortality cost is due to smoking, mental illness may account for a larger portion of 
the decrease to quality of life, which I did not examine here. 
The fact that smoking and serious mental illness comorbidity reduce life expectancy by 
nearly 15 years is appalling considering that the former can be avoided completely and 
the effects of the latter can be mitigated through effective prevention and treatment 
efforts. Though life expectancy is already reduced for individuals with mental disorders, 
important gains could be made by aiding those with mental illness to quit smoking, or by 
preventing them from ever starting to smoke. 
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Appendix 
Supplementary materials, including more detailed lifetables, can be found online through the American Journal of 
Preventive Medicine.41 
The following tables are results using the PHQ-9 measure for depression. 
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Table 2-5. All-cause mortality hazard ratios by age group, NHANES 2005-2010 
 Ages 25-34 35-44 45-54 55-64 65-80 Full sample 
Current smoker 5.164** 2.171 2.964*** 2.241*** 2.547*** 2.578*** 
  (1.284 - 20.770) (0.585 - 8.057) (1.430 - 6.145) (1.276 - 3.937) (1.748 - 3.711) (1.890 - 3.516) 
Former smoker†  0.674 1.893 1.178 1.336 1.359 
   (0.059 - 7.637) (0.718 - 4.987) (0.577 - 2.402) (0.917 - 1.947) (0.896 - 2.061) 
Depressed 1.642 1.998 1.211 1.244 1.915*** 1.628*** 
  (0.373 - 7.215) (0.601 - 6.638) (0.631 - 2.325) (0.733 - 2.109) (1.184 - 3.099) (1.159 - 2.288) 
Male 3.136 0.774 1.681 1.180 1.748*** 1.490*** 
  (0.794 - 12.378) (0.248 - 2.418) (0.886 - 3.190) (0.763 - 1.824) (1.338 - 2.284) (1.168 - 1.902) 
High school or less 1.666 3.181 2.322* 1.452 1.886** 1.920*** 
  (0.130 - 21.320) (0.409 - 24.755) (0.877 - 6.151) (0.752 - 2.802) (1.070 - 3.326) (1.387 - 2.657) 
Some college 4.245 3.306 2.464 1.339 1.624 1.836*** 
  (0.385 - 46.804) (0.343 - 31.885) (0.699 - 8.680) (0.600 - 2.992) (0.871 - 3.031) (1.212 - 2.783) 
Hispanic 1.153 0.745 0.690 1.301 0.692 0.824 
  (0.184 - 7.217) (0.296 - 1.875) (0.326 - 1.461) (0.724 - 2.338) (0.442 - 1.084) (0.636 - 1.067) 
Black, NH 4.118* 0.404 1.625 2.252*** 1.018 1.386*** 
  (0.920 - 18.426) (0.118 - 1.387) (0.868 - 3.044) (1.378 - 3.681) (0.672 - 1.540) (1.094 - 1.754) 
Other race, NH†    0.769 2.031 0.772 
     (0.099 - 5.971) (0.634 - 6.505) (0.277 - 2.150) 
Age 0.851* 1.235 1.368 1.050 1.051 1.117** 
  (0.710 - 1.021) (0.772 - 1.976) (0.886 - 2.113) (0.862 - 1.278) (0.943 - 1.171) (1.025 - 1.217) 
Year of birth  1.199 1.195 1.006 0.942 1.033 
   (0.811 - 1.772) (0.820 - 1.742) (0.854 - 1.184) (0.848 - 1.046) (0.950 - 1.124) 
No. of observations 2438 2502 2541 2326 2624 12,418 
*** p<0.01, ** p<0.05, * p<0.1; 95% CI presented below hazard ratios; Reference groups omitted from table: never smoker, college graduate, 
non-Hispanic, white NH; NH = non-Hispanic; †Coefficients for former smoker 25-34 and other race, NH ages 25-54 could not be estimated due 
to collinearity with the mortality variable. 
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Table 2-6. Smoking attributable fraction (SAF) of deaths, NHANES 2005-2010 
SAF 
0.60 
(0.20 - 0.83) 
P1 
0.42 
(0.38 - 0.46) 
P2 
0.20 
(0.17 - 0.24) 
RR1 
4.24 
(1.83 - 9.84) 
RR2 
1.69 
(0.58 - 4.98) 
P1 = current smoker prevalence among those with depression; 
P2 = former smoker prevalence among those with depression; 
RR1 = mortality hazard ratio for current smokers with depression 
relative to never smokers with depression; RR2 = mortality 
hazard ratio for former smokers with depression relative to never 
smokers with depression; 95% CI presented below estimates. 
 
The National Health and Nutrition Examination Survey (NHANES) began screening for 
depression annually in 2005 using the Patient Health Questionnaire-9 (PHQ-9). This nine-
item questionnaire screens for the nine criteria for major depressive disorder according 
to the Diagnostic and Statistical Manual on Mental Disorders (DSM-IV) and is a widely 
used and validated measure for depression. The PHQ-9 asks about frequency of 
experiencing 1) little interest or pleasure in doing things 2) feeling down, depressed, or 
hopeless, 3) trouble falling or staying asleep, or sleeping too much, 4) tired or having little 
energy, 5) poor appetite or overeating, 6) bad about oneself or like a failure, 7) trouble 
concentrating, 8) moving more slowly than usual or being fidgety and restless, 9) suicidal 
thoughts, over the past two weeks. Each item is scored 0-3 for “not at all,” “several days,” 
“more than half the days,” and “nearly every day.” Depression is defined as score of 10 
or greater. Data from the NHANES 2005-2006, 2007-2008, and 2009-2010 cycles were 
linked to the 2011 National Death Index mortality follow-up. 
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Chapter 3 – Lifetime prevalence of major depressive episodes and adjustment of 
recall error through simulation modeling 
 
Background 
The National Survey on Drug Use and Health (NSDUH) is one of the main sources of 
surveillance information on population mental health in the U.S. According to the NSDUH, 
an estimated 16.2 million adults (6.7% of the population) have had at least one episode 
of major depression (MD) in the past year.1 Of these individuals, nearly two-thirds 
experienced severe impairment due to MD, affecting their home management, 
relationships with others, social life, and ability to work. MD is the most common mental 
disorder in the general population and a leading contributor to disability worldwide.2 In the 
U.S., MD accounts for 8.3% of all years lived with disability, and carries the heaviest 
disability burden of any mental and behavioral disorder.3 People with MD have shorter 
life expectancies and increased risk of death, including suicide.4-7 MD is also associated 
with significant productivity loss.8,9 Still, the extent of the burden of depression and its 
impact on population health is likely misestimated by available survey data.  
Cross-sectional surveys such as NSDUH assess lifetime history of psychiatric disorders 
retrospectively. This is problematic, as longitudinal studies have shown that retrospective 
assessments are prone to underreporting.10 For example, the Baltimore Epidemiological 
Catchment Area (ECA) Study found that over a 25-year follow-up period, lifetime 
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prevalence of MD was nearly 3 times greater (4.5% vs. 13.1%) using cumulative 
evaluations compared to retrospective evaluations.11 Moreover, cross-sectional surveys 
that cover a broad age range unexpectedly show that the lifetime prevalence of MD 
declines, rather than increases, with age.12 For example, the National Comorbidity Survey 
–Replication (NCS-R) identified lifetime prevalence of MD as 16.6% for all adults, where 
MD increased as expected through ages 18-44, then dropped to 10.6% of those above 
age 60.13 This pattern could be explained by differential mortality and symptomatic 
differences in depression among older adults,14 or differences in MD incidence by birth 
cohort. However, failure to recall earlier depressive episodes,15 particularly among older 
people, could also result in decreasing lifetime prevalence with age. 
Surveys of population mental health such as the NSDUH provide timely assessments of 
psychopathology, which is useful for service planning. However, they may underestimate 
lifetime prevalence of MD due to their reliance on retrospective reporting. On the other 
hand, prospective cohort studies that address recall bias are costly to implement, often 
specific to a particular geographic location (e.g., Baltimore site of the ECA), or have only 
a few waves of data (e.g., National Epidemiologic Survey of Alcohol and Related 
Conditions; NESARC). In the absence of sufficient data to fully estimate the burden of 
MD in the population, simulation modeling approaches can fill in gaps in our 
understanding of the epidemiology of depression.16-18  
Simulation modeling is an analytic approach that uses existing information to represent 
processes that contribute to the observed data. To date, very few models of depression 
consider the issue of declining lifetime prevalence of MD with age. One microsimulation 
study using data from Australia and the Netherlands addressed recall error to re-estimate 
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lifetime depression prevalence in the population.19 Another discrete event simulation 
study investigated decreasing lifetime prevalence of MD by age in Canada.20 No such 
analysis has used simulation modeling to evaluate the potential impact of recall error on 
prevalence estimates of lifetime depression in the U.S. 
In this chapter, I develop a system dynamics model of MD episodes, combining both 
annual cross-sectional NSDUH data and prospective cohort data from the Baltimore ECA, 
to explicitly model recall error and associated mismeasurement of MD. I use this model 
to generate incidence and recall error parameters that do not yet exist in the literature, 
and to ultimately produce revised national estimates for lifetime prevalence of MD.  
Methods 
Data sources 
The NSDUH is an annual nationally-representative household cross-sectional survey of 
~70,000 civilian noninstitutionalized people ages 12 and above. The NSDUH assesses 
MD using criteria derived from the Diagnostic and Statistical Manual of Mental Disorders 
(DSM).21 I use data for the adult (age ≥18) population (~50,000 respondents), because 
survey questions for MD differ between youth and adults, and are thus not comparable 
for combined analysis.22,23 The survey is directed by the Substance Abuse and Mental 
Health Services Administration (SAMHSA) Center for Behavioral Health Statistics and 
Quality and conducted by RTI International.23 Data on drug, alcohol, and tobacco use are 
collected as well as mental health indicators such as psychological distress and 
depressive symptoms. The survey ensures respondent confidentiality as no personally 
identifying information is included with survey responses. Participants use audio 
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computer-assisted self-interview software to respond to sensitive questions and receive 
a $30 incentive at the end of the survey. This data source represents the most historically 
comprehensive information on patterns of depression24 with comparable measures for 
the years 2005-2015. 
The Baltimore Epidemiologic Catching Area (ECA) Study is a longitudinal survey that 
follows a 1981 baseline cohort of 3,481 adult household residents in East Baltimore and 
repeats assessments in 1993, 1996, and 2004. Participants provide information about 
their depressive episodes based on the question “During that year, was there ever a time 
when you were feeling sad, depressed, or blue, and had some of these other problems 
like [list of DSM-IV criteria for MDD]?”25-27 Memory anchors with key life events are used 
to help place periods of depression within each respondent’s personal life history.  
Measures 
A MD episode is a period lasting two weeks or more during which the respondent reports 
experiencing at least five of the following nine symptoms: 1) depressed mood most of the 
day, 2) markedly diminished interest or pleasure in activities most of the day, 3) significant 
changes in weight or appetite, 4) insomnia or hypersomnia, 5) psychomotor agitation or 
retardation, 6) fatigue, 7) feelings of worthlessness, 8) diminished ability to think or 
concentrate, and 9) recurrent thoughts of death or suicide ideation. These symptoms 
were asked about both over their lifetime and in the past year. The NSDUH measure of 
MD does not apply DSM hierarchy exclusions for episodes due to illness, bereavement, 
and/or substance use disorders.   
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Model overview 
There are three possible MD states for the population in the model. I define current MD 
(black) as an episode within the past 12 months, including a first or recurrent episode. I 
define former MD as individuals who report a lifetime history of at least one MD but have 
not had an episode within the past year (gray). I define never MD as those who report no 
lifetime history of MD (white). A key innovation of this model is that it includes a ‘recall 
error’ compartment for people who report no lifetime history of MD, but who are actually 
former MD.  
Figure 3-1 provides an overview of the model structure. I use a compartmental model with 
separate stocks (boxes) for each depressive state and transition probabilities governing 
the flow (arrows) of individuals moving across them. This model evaluates aggregate-
level patterns and does not track individual trajectories of depression (e.g. episode 
duration, number of previous episodes).  
There are three possible MD states for the population in the model. I define current MD 
(black) as an episode within the past 12 months, including a first or recurrent episode. I 
define former MD as individuals who report a lifetime history of at least one MD but have 
not had an episode within the past year (gray). I define never MD as those who report no 
lifetime history of MD (white). A key innovation of this model is that it includes a ‘recall 
error’ compartment for people who report no lifetime history of MD, but who are actually 
former MD.  
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Figure 3-1. Model diagram of depressive states and transitions 
 
MD = Major Depression; Diamond = annual probabilities estimated during model 
calibration; Never MD = individuals with no lifetime history of MD; Current MD = 
individuals with a past year MD; Former MD = individuals with lifetime history of 
MD but no MD episode in the past. Recall error = individuals who report no lifetime 
history of MD but are modeled as former MD.  
 
I simulate a population in which all individuals begin in the never MD state at age zero 
based on U.S. Census Bureau population estimates for the years 2005-2015.28 While I 
exclude children from the data sources, the model simulates individuals from birth until 
death, with onset of depression occurring as early as age 12. I model a ‘burn-in’ period in 
which the population is simulated beginning in 1900, with new births and deaths each 
year, so that the model achieves observed depression patterns by 2005.  
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Table 1 shows parameters used or calibrated for the model. As individuals age each year, 
they may have a first MD episode according to age at onset of MD incidence rates from 
the Baltimore ECA  Study.25 The ECA study identified 71 new cases of MD among 1,920 
respondents representing 23,698 person-years of exposure. This study found that 
incidence peaked when respondents were in their 30s, with a smaller peak during their 
50s. Because the Baltimore ECA did not include incidence rates for females ages < 22 
and males ages < 29, where no data are available, I estimate the probability of a first MD 
episode for younger ages, 12-21 in females and 12-28 in males, during model calibration. 
Following a first MD episode, individuals can recover into the former MD compartment. 
Annual recovery probabilities are treated as identical for males and females, and as 
constant across all ages. I calculated recovery and recurrence transition probabilities 
based on data from the Baltimore ECA.26 Likelihood of recovering from an episode is the 
same regardless of whether individuals are in a first or subsequent episode, based on 
evidence showing no significant difference in rates of recovery by number of prior 
episodes.29  
Table 3-1. Model parameters 
Parameter Model estimates 
1st MD incidence 
probabilities  
Age at onset of MD episode incidence for females ages 22+ and males 
age 29+ in the Baltimore-ECA cohort study.25 Cubic natural splines for 
MDE incidence with knots at ages 13 and 18 were used to estimate 
probabilities among females ages 12-21 and males ages 12-28. 
MD recovery 
probabilities  
Annual probability of recovery calculated from 85% cumulative recovery 
from 1st MD over 10 years in the Baltimore-ECA cohort study.26  
Annual probability =  1 – (1 − 𝐶𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝐼𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒)(
1
𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑌𝑒𝑎𝑟𝑠⁄ ) 
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                              = 1 − (1 − 0.85)(
1
10⁄ ) = 0.173). 
MD recurrence 
probabilities 
Annual probability of recurrence calculated from 45% cumulative 
recurrence after 1st MD over 10 years in the Baltimore-ECA cohort 
study.26 Annual probability  =  (1 – (1 − 0.45)(
1
10⁄ ) = 0.058). 
Annual probability 
of death 
Age, gender, and birth-cohort specific death probabilities from the 
Human Mortality Database, which relies on information from the National 
Vital Statistics System.30 
Relative risk of 
mortality for 
lifetime history of 
MD episodes  
Pooled relative risk of mortality for people with lifetime history of MD 
(RR=1.71, , 95% CI: 1.54 to 1.90) estimated from a meta-analysis of 43 
studies.5 
 
Former MD individuals can shift into the ‘recall error’ compartment based on calibrated 
estimates for the annual probability of underreporting past episodes. Since the aim is to 
assess the extent to which individuals fail to report histories of MD, I assume no 
inaccuracies due to overreporting of depressive episodes. Like those who are former MD, 
this group can then have a recurrent MD episode. 
Finally, individuals across all compartments exit the model based on age, birth-cohort, 
and year-specific death probabilities. I applied an elevated risk of death to all ages among 
those with lifetime MD using a pooled relative risk of mortality (RR=1.71, , 95% CI: 1.54 
to 1.90) from a meta-analysis of 43 studies,5 that is nearly identical to an estimate from 
another review.31 All surviving individuals exit the model by death at age 99. I developed 
the model using R version 3.1.3.32 Given known differences in depression patterns by 
gender, I model females and males separately.33 
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Calibration 
I calibrate the model to reproduce NSDUH depression patterns by age and gender using 
the ‘Bhat’ and ‘splines’ packages in R.32,34 Specifically, I fit NSDUH data across three MD 
states and five age groups (18-25, 26-34, 35-49, 50-64, 65+) for a total of 15 distinct 
groups for males and females. I use the Davidon-Fletcher-Powell optimization algorithm 
to search for parameter estimates that minimize the sum of squared differences between 
the model and the NSDUH data for the years 2005-2015. During calibration, I fitted 
individuals in the ‘recall error’ compartment as part of the never MD population. 
Parameter estimation 
I estimate parameters for first onset of MD for females ages 12-21 and males ages 12-28 
using cubic natural splines to identify coefficients for the annual age-specific probability 
of a first MD. This extends previously reported curves for age at MD onset to include 
youth and young adults,25 and ensures that the model produces accurate estimates by 
age 18. The splines are given three degrees of freedom with knots at age 13 and 18. I 
assume no episodes of MD occur prior to age 12, because data suggest that only 0.50-
0.75% of children show signs of depression by age 11.35 
During calibration, I estimate underreporting for each of five age groups to align with the 
NSDUH data and allow annual probabilities to range from 0 to 1. Because the NSDUH 
top-codes all ages above 65, I estimate the same probabilities for the entire 65-99 
category. The model assumes zero probability of underreporting of past MD among 
individuals ages < 18.  
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Sensitivity analysis 
I assess the impact of three parameters: recovery, recurrence, and the relative risk of 
mortality among people with a history of MD, on two main outcomes of interest: (1) the 
proportion of the adult population that fails to recall past history of MD and (2) lifetime 
prevalence of MD. These parameters are assessed with Latin hypercube sampling, which 
enhances efficiency and reduces the number of model runs necessary to produce 
accurate estimates, using the package ‘pse’ in R.36,37 I sample 200 parameter 
combinations, with each run re-fitting and re-estimating splines coefficients for MD 
incidence probabilities and age group-specific underreporting probabilities. Since there is 
substantial uncertainty surrounding the parameters for recovery and recurrence from MD. 
I sample values from a uniform distribution range that halved (50% decrease) and 
doubled (100% increase) base estimates. Values for the relative risk of mortality 
associated with ever having a MD episode are sampled from the normal distribution (RR 
= 1.71, 95% CI: 1.54-1.90) for the relative risk of mortality associated with MD.5  
Results 
In the NSDUH, for all age groups except for ages 65+, lifetime prevalence of MD 
fluctuated slightly from year to year but generally ranged from 16.5% to 20.3% for 
females, and 9.0% to 12.8% for males (Figure 3-2). Lifetime prevalence was markedly 
lower in the oldest age group, with point estimates ranging from 5.7% to 9.5% for females, 
and from 2.8% to 5.6% for males.  
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Figure 3-2. Lifetime MD prevalence by age group without recall error adjustment, 
United States, 2005-2015. 
 
MD = Major Depression; Lines = model estimates without recall error adjustment; 
Dots = National Survey on Drug Use and Health data with 95% confidence 
interval bands (vertical lines).  
 
After calibration, the model estimates for lifetime MD prevalence by age group without 
recall error adjustment corresponded closely to the NSDUH data as shown in Figure 3-2. 
For comparison, I categorize individuals with recall error in the model as never MD. For 
females, when those with recall error were excluded from lifetime MD estimates, 
prevalence decreased slightly with each successive age group, before dropping 
dramatically for the oldest age group. By the year 2015, prevalence was 18.2% for 18-25 
year olds, 18.1% for 26-34 year olds, 17.9% for 35-49 year olds, 17.6% for 50-64 year 
olds, and 9.4% for ages 65 and above. For males, lifetime prevalence increased slightly, 
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then decreased, with age: lifetime MD prevalence was 10.2% for 18-25 year olds, 10.9% 
for 26-34 year olds, 11.1% for 35-49 year olds, 10.4% for 50-64 year olds, and 5.3% for 
those 65+ in the year 2015. Model estimates for each age group were relatively stable 
over time, with <0.1% absolute changes in prevalence over the 11-year period. For a 
comparison that includes recall error adjustment, see Appendix Figure 3-6. 
I present the probabilities of first lifetime MD episode as used in the model in Figure 3-3. 
Black dots and circles represent previously reported data from the Baltimore ECA for 
women ages ≥ 22 and men ages ≥ 29.25 Earlier research from the Baltimore ECA among 
adults showed bimodal MD incidence distributions, with peaks in the 30s and 50s age 
ranges. The calibrated estimates show higher risk of a first episode at younger ages for 
both females (solid line) and males (dashed line). Annual probabilities of first MD episode 
peak at age 18 among females (0.047) and at age 16 among males (0.014). This is 6.3 
times greater than the highest peak based on previously reported data (0.008 at age 30), 
and 3.4 times greater than the highest previously reported rate among men (0.004 at age 
40). Among youth and young adults, extrapolated probabilities of MD onset were 
substantially lower for males than for females, though the splines show a wider and more 
rounded peak.  
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Figure 3-3. Annual probability of 1st major depressive episode 
 
Solid line = Females ages 12-21 calibrated model estimates; Dashed line = Males 
ages 12-28 calibrated model estimates; Black Dots = incidence probabilities for 
female age at onset of major depressive disorder (MDD) in the Baltimore 
Epidemiological Catchment Area (ECA) Study; Circles = incidence probabilities for 
male age at onset of MDD in the Baltimore ECA Study.  
    
I identified consistent patterns for the probability of underreporting a past MD episode for 
females (solid line) and males (dashed line), as shown in Figure 3-4. The calibrated model 
estimated zero probability of underreporting past MD for both males and females ages 
18-25. The estimated proportion of former MD individuals who do not report their past 
episodes was higher for females (15.2%) than for males (10.5%) for those ages 18-25 
and similar for ages 26-34 (10.1% vs. 8.8%) and 35-49 (12.0% vs. 12.7%). Probabilities 
of underreporting were dramatically higher for those ages 65+, with 92% and 71.9% of 
former MD females and males do not report their histories of MD. This represents more 
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than seven-fold and five-fold increases compared to the preceding age groups for females 
and males respectively.  
Figure 3-4. Past major depressive episode underreporting probabilities by age, 
United States 
 
Solid line = Females; Dashed line = Males; model estimates calibrated for age 
groups 18-25, 26-34, 35-49,50-64, and 65+. Annual probabilities for individuals 
age <18 fixed at zero.  
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The model estimates 13.1% of women and 6.5% of men failed to report their histories of 
MD (Figure 3-5). Sensitivity analysis showed that 95% of values for the proportion of 
adults that underreport a past episode ranged from 8.6% to 16.9% for females and 4.2% 
to 8.5% for males (Appendix Figure 3-7). Individuals who fail to report their past 
depression represent an increasing share of those with lifetime MD with each successive 
age category; this proportion is lowest for ages 26-34 when 6.9% of females and 2.9% of 
males make up this group, and highest for ages 65+ at 21.7% of females and 11.5% of 
males. People who fail to report their past depression make up more than two-thirds of 
those with lifetime MD at age 65+.  
Figure 3-5. Adult lifetime MD prevalence by age group with recall error 
adjustment, United States, 2015 
 
MD = Major Depression; Distribution of the adult population with current MD 
(black), former MD (gray), former MD with recall error (diagonal hatching 
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pattern), and never MD (white). Numbers represent the percent of individuals 
with lifetime MD. Numbers in parentheses represent the percent of individuals 
with recall error who fail to report lifetime MD. 
 
Figure 3-5 shows estimated prevalence of lifetime MD by age group and gender in 2015. 
Approximately 10% of women and 6% of men had current MD, and this remained 
relatively constant across age groups. The recall-corrected model estimated that 28.7% 
of women and 16.0% of men had a lifetime history of MD. During sensitivity analysis, 95% 
of estimates for lifetime prevalence of MD fell between 27.8% and 31.3% among females 
and between 15.4% and 17.6% among males (Appendix Figure 3-7). The proportion of 
the population with a lifetime history of MD increases with age until peaking in the 50-64 
age group, where 32.8% of females and 19.1% of males had a history of a MD in their 
lifetimes, then decreases for those ages 65 and above to 31.1% and 16.9% respectively. 
Thereafter, the oldest 65+ age group shows slightly lower lifetime MD prevalence 
compared to younger adults, due to differential mortality. 
Discussion 
This simulation model quantifies the impact of recall error on lifetime prevalence of MD in 
the general U.S. population. I found that more than 40% of adults with a lifetime history 
of MD failed to report their history of MD in cross-sectional surveys. This indicates that 
lifetime prevalence of MD is considerably higher after accounting for underreporting 
among those without a current MD. The findings corroborate simulation studies from other 
countries that show lifetime prevalence of depression is dramatically higher than indicated 
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by retrospective analyses.19,38 Our recall-corrected estimates also show the expected 
pattern of increasing lifetime prevalence with age, with a minor decrease in the oldest age 
group that can attributed to differential mortality.  
This model is strengthened by its relative structural simplicity, its remarkably close fit with 
11 years of nationally-representative survey data, and the use of age-cohort specific 
mortality rates. This simple yet comprehensive simulation model derives parameters for 
MD onset, recovery, and recurrence from the nation’s longest-running psychiatric 
epidemiologic prospective cohort study. Furthermore, sensitivity analysis suggests that 
even with considerable uncertainty surrounding the extent to which adults underreport 
their past episodes, lifetime MD prevalence estimates fall within relatively narrow ranges.  
I also found that the probability of a first MD episode is higher during adolescence than 
adulthood. By extrapolating probabilities to younger ages, I report plausible depression 
incidence data that could not otherwise be obtained through survey data.  Youth and adult 
measures for depression are not directly comparable, nor are they generally used within 
the same surveys.14 Our incidence estimates also support other data that show 
depressive symptoms become increasingly prevalent during adolescence.35,39  
There are several alternative explanations for the lower lifetime MD prevalence among 
adults ages 65+ beyond recall error. They may interpret prior depressive symptoms 
differently, potentially in a more positive manner.40 For example, older adults are less 
likely to endorse depressive symptoms, and when they do experience symptoms they are 
more likely to be categorized as ‘minor’ depression.41,42 If MD incidence is rising over 
time, as some have argued,43 it is possible that earlier birth cohorts have lower rates of 
 57 
 
depression compared to recent birth cohorts. Even if the absence of a real increase in 
incidence, more recent cohorts may have greater mental health awareness, making them 
more likely to report symptoms.  Finally, because people with depression have increased 
mortality risk, a larger proportion of them would be deceased in the oldest age group so 
their absence would lead to lower lifetime MD prevalence. However differential mortality 
does not explain unchanging patterns of lifetime MD prevalence during ages 25-64 when 
recall error still occurs. Because the U.S. population is aging44 and recall error increases 
with age, this will further underestimate the true lifetime burden of depression.  
Findings should be interpreted in light of study limitations. Because the public-use 
NSDUH data does not disaggregate its oldest age group, underreporting parameters 
were estimated for all individuals in this group. This results in a notable ‘jump’ in 
probabilities from the 50-64 age group to ages 65+. I previously used cubic natural splines 
to estimate the annual probability of forgetting which generated smoother curves across 
all ages. However, I found that using a 0 to 1 probability for each age group was both 
simpler to implement and capable of achieving a similar fit with survey data during 
calibration. 
In the absence of reliable age-specific depression mortality rates, I had to apply a single 
relative risk of mortality point estimate for all individuals with lifetime MD. Some studies 
suggest that there is in fact no increased risk of death associated with major depressive 
disorder alone, and existing estimates may be confounded by concurrent health decline.45 
However the model does not consider differences by sociodemographic groups, and 
individuals with depression are more likely to live in poverty which puts them at higher 
risk of mortality overall.46 This study also does account for high smoking rates among 
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those with depression, when smoking contributes substantially to mortality and reduced 
life expectancy among people with mental illness.47,48 Even if depression itself confers a 
relatively small increase in mortality risk, individuals in the population with a history of 
depression are likely to still have higher probabilities of death. Although it is unclear how 
mortality risk for depression would change over the life course, sensitivity analysis show 
that varying a single mortality estimate did not change the study conclusions. 
Due to the limited years of survey data, I were unable to examine period or cohort effects 
that may contribute to variation in lifetime MD prevalence, as discussed above. The 
NSDUH does not distinguish between depressive episodes associated with unipolar 
depression and bipolar disorder, so the exclusion of individuals with bipolar disorder 
would slightly lower prevalence estimates. In addition, recovery and recurrence rates 
were derived them from a single cohort study. However sensitivity analyses revealed that 
varying these parameters did not change the inferences drawn from the model: recall 
error plays a significant role in the severe underestimation of lifetime MD prevalence 
based on survey data.  
High probabilities of recall error of MD episodes are an inevitable consequence of 
assessing depression symptoms in the general population. However, the alternative of 
relying on reports of clinical diagnosis  would still substantially underestimate the burden 
of depression because ~37% of adults with MD do not receive any treatment for their 
depression.49 Future studies should evaluate how survey inaccuracies lead to 
underestimation of the economic and disability burden of depression in populations. 
Research should also investigate who exactly fails to report their past experiences with 
depression and why. It is likely that such individuals have mild symptoms, episodes of 
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relatively short duration, or only a single episode across their lifetime. The stigma 
associated with having a history of a mental disorder is another likely explanation for their 
widespread underreporting. Future research should investigate the factors that contribute 
to under-reporting and recall error, and evaluate the implications of these underestimates 
for understanding the social, economic, and disability burden of depression in the 
population.  
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Appendix 
Figure 3-6. Lifetime MD prevalence by age group with recall error adjustment, 
United States, 2005-2015 
 
MD = Major Depression. Lines = model estimates with recall error (underreporting) 
adjustment; Dots = National Survey on Drug Use and Health data with 95% 
confidence interval bands (vertical lines).  
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Figure 3-7. Uncertainty distributions of lifetime MD prevalence and recall error, 
adults ages 18-99, United States 
 
MD = Major Depression; Red = Females; Blue = Males; Vertical dashed line = 
mean value; A) Latin hypercube sampling results for lifetime MD prevalence with 
95% of values for females between 27.8% and 31.3% and for males between 
15.4% and 17.6% among males; B) Latin hypercube sampling results for the 
proportion of adults with former MD that underreport lifetime MD, with 95% of 
estimates from 8.6%-16.9% for females and from 4.2%-8.5% for males. 
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Chapter 4 - Modeling smoking-related mortality and disparities for adults with 
depression 
 
Background 
Tobacco use and major depression are leading causes of death and disability in the U.S.1 
According to the National Survey on Drug Use and Health (NSDUH), 17.8% of adults are 
past 30-day smokers, and at least 1 in 6 Americans experiences major depression (MD) 
in their lifetime.2-4 Annually approximately 6.7% of the U.S. adult population has had a 
MD episode in the past year, representing 16.2 million people.5 Smoking and depression 
are also highly associated with each other,6 and smokers with comorbid mental illness 
are considered a high priority group for intervention.”7 The disparity in smoking rates 
between those with and without depression is substantial. Based on the 2015 NSDUH, 
31.2% of women and 35.8% of men with current MD are smokers, compared to 16.7% of 
women and 23.6% of men with no lifetime history of MD. Not only are people with 
depression more likely to start smoking, they are also less likely to quit.8-10 The health 
burden for smokers with depressive disorders is high – they have elevated risk for disease 
and death due to their tobacco use,11-14 as well as for their depression per se. In Chapter 
2, I showed that for smokers with serious mental illness, much of their reduced life 
expectancy may be due to smoking alone.15  
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The mechanisms that lead to higher observed smoking rates among the depressed are 
not well-understood; however, recent longitudinal studies and systematic reviews have 
concluded that the relationship between depression and smoking is likely bi-
directional.16,17 Smoking and depression comorbidity is likely due to a combination of 
shared risk factors and neurobiological mechanisms.18-20 Research supports the notion 
that smoking increases one’s susceptibility to depression through neurophysiological 
changes,21-23 and nicotine dependence has been shown to cause mood fluctuation and 
heighten stress pathways.24-26 Other studies suggest that underlying genetic and social 
vulnerability may partly explain their co-occurrence.27-29 Yet the association between 
smoking and depression remains, even after adjusting for demographic covariates30-32 
and other psychiatric disorders33,34. Major depression is a risk factor for future smoking 
and nicotine dependence,35-38 and tobacco use predicts subsequent symptoms of 
depression by contributing to psychological distress and worse cognitive 
functioning.24,35,39-43 These feedback effects imply that changes in either mental well-
being or smoking behavior is likely to have effects on the other. Though people with 
mental illness are as motivated to quit smoking as the general population,44,45 traditional 
tobacco control policies may have limited effectiveness for individuals whose mental 
states compromise aspirations for longer-term health and who may be inherently more 
susceptible to nicotine addiction.46,47  
To date, very few population models of smoking have accounted in detail for differences 
in smoking patterns by relevant social factors, and none of have considered differences 
by mental health status.48-55 Similarly, although some health economic56-61 and dynamic 
models62,63 for depression exist, these do not explicitly account for smoking comorbidity. 
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A model of smoking and mental illness comorbidity can be used to evaluate the potential 
effects of health interventions with the potential to reduce tobacco use disparities and the 
burden of smoking in populations with behavioral health conditions. 
In this chapter, I develop a model of smoking and depression comorbidity in the U.S. adult 
population using a system dynamics approach. System dynamics models, also referred 
to as compartmental models, are composed of ‘stocks’ of homogeneous individuals within 
a health state (e.g. people with current MD) and ‘flows’ governed by differential equations 
characterizing the rates at which individuals move between health states (e.g. MD 
incidence or recovery).64 These aggregate-level models are ideal for testing macro-level 
upstream policies in systems with nonlinearity, feedback loops, and time delays between 
events (e.g. smoking initiation) and future consequences (e.g. disease and death). A top-
down system dynamics approach to studying smoking and depression comorbidity is 
ideal given these feedback effects, as well as the long time lag between smoking, 
depression, or interventions, and their subsequent impacts on population health 
outcomes.  
The model considers the dynamics of major depression and smoking behaviors, 
projecting future smoking prevalence by depressive state, depression prevalence, and 
smoking-attributable deaths from 2016 to 2050.  
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Methods 
Data Sources 
I develop and validate the model using data from the National Survey on Drug Use and 
Health (NSDUH), an annual nationally representative survey of the non-institutionalized 
population in the U.S. adults ≥18+. Data on smoking behaviors, and depressive episodes 
are publicly available through the NSDUH for the years 2005-2015. The NSDUH provides 
consistent measures for smoking and includes data on depression and mental health 
service utilization from 2005 to 2015.65 Though the NSDUH is a cross-sectional survey, 
compared to other surveys of mental health in the U.S., it is currently the most historically 
comprehensive data source, with annual data that enables analyses of trends in 
depression and tobacco use over time by mental health status.66 
Measures 
I use modified definitions for cigarette smoking in order to be consistent with other input 
data sources used in the model, and to simulate permanent smoking cessation without 
relapse (see next section). The standard definition for current smoking in the NSDUH is 
smoking part or all of a cigarette at least once in the past 30 days (Table 4-1. Smoking 
definitions comparisonTable 4-1). For this model, current smokers are individuals who 
smoked at least 100 cigarettes in their lifetime and smoked anytime within the past year. 
Former smokers are those who have smoked at least 100 cigarettes in their lifetime but 
who have not smoked at any point in the last year. This stricter definition for current 
smokers includes those who have quit smoking less than one year prior to survey 
assessment and avoids the problem of modeling cessation relapse in the model by 
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categorizing former smokers as those who likely have permanently quit. Never smokers 
are defined as those who have never smoked at least 100 cigarettes in their lifetime. 
Table 4-1 compares the model definitions with those used in national surveys and in other 
modeling studies. 
Table 4-1. Smoking definitions comparison 
 Current smoker Former smoker Never smoker 
National Health 
Interview Survey 
(NHIS) 
Currently smokes every 
or some days and has 
smoked at least 100 
cigarettes in their lifetime 
Smoked at least 100 
cigarettes in their 
lifetime and does not 
currently smoke 
Smoked less 
than 100 
cigarettes in 
their lifetime 
National Survey on 
Drug Use and Health 
(NSDUH) 
Smoked part or all of at 
least one cigarette in the 
past 30 days 
Has ever smoked part 
or all of a cigarette but 
not within the past 30 
days 
Has never 
smoked part or 
all of a 
cigarette 
Cancer Intervention 
and Surveillance 
Modeling Network 
(CISNET) lung 
consortium 
Smoked at least 100 
cigarettes in their lifetime 
and smoked within the 
past 2 years 
Smoked at least 100 
cigarettes in their 
lifetime and last 
smoked more than 2 
years ago 
Smoked less 
than 100 
cigarettes in 
their lifetime 
Modified definition  
used by model 
Has smoked at least 100 
cigarettes in their lifetime 
and has smoked part or 
all of a cigarette within 
the past year 
Smoked at least 100 
cigarettes in their 
lifetime but has not 
smoked at all within 
the past year 
Smoked less 
than 100 
cigarettes in 
their lifetime 
 
The NSDUH adult depression modules screen for lifetime and past year experience of a 
MD episode. The survey uses MD episode criteria derived from the Diagnostic and 
Statistical Manual or Mental Disorders (DSM-IV) – an individual must report at least five 
of the following nine symptoms for at least two weeks: 1) depressed mood most of the 
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day, 2) markedly diminished interest or pleasure in activities most of the day, 3) significant 
changes in weight or appetite, 4) insomnia or hypersomnia, 5) psychomotor agitation or 
retardation, 6) fatigue, 7) feelings of worthlessness, 8) diminished ability to think or 
concentrate, and 9) recurrent thoughts of death or suicide ideation.67 MD prevalence in 
the NSDUH is greater than estimates reported elsewhere,68,69 as the NSDUH does not 
exclude depressive episodes caused by illness, bereavement, substance use or other 
psychiatric disorders such as bipolar disorder.70  
For this model, people with current MD have had a MD episode in the past year. Those 
who with former MD have had a MD in their lifetime, but not in the past year. Those who 
are never MD have never had a MD episode in their lifetime. Cross-sectional surveys of 
depression that rely on retrospective evaluations have been known to lead to substantial 
underestimation of lifetime history of depression.71 The model explicitly accounts for the 
probability of recall error, so that individuals reporting no lifetime history of depression 
may actually be formerly depressed. Rates of recall bias by age were estimated during 
model calibration (See Chapter 3). 
I developed this model by first separately fitting smoking-only and depression-only sub-
models to smoking and depression data respectively. Once I calibrated both of these sub-
models, I combined them into the full smoking and depression comorbidity model and re-
calibrated to fit survey data on smoking prevalence by depressive status and vice versa. 
The full model of smoking and depression comorbidity specifically integrates and 
estimates known and unknown interaction effects between smoking initiation and 
cessation, and depression onset, relapse and recovery. I conducted all analyses using R 
version 3.1.3.72  
 71 
 
Smoking sub-model 
I consider three mutually exclusive smoking states in the smoking-only sub-model (Figure 
4-1): never smoker, current smoker, and former smoker. Individuals are added to the 
model at birth as never smokers who can become current smokers, and then former 
smokers, based on initiation and cessation probabilities developed by the Cancer 
Intervention and Surveillance Modeling Network (CISNET) lung consortium.73 
Probabilities age, gender, and birth cohort were derived from the National Health 
Interview Surveys (NHIS) 1965-2015. CISNET projections for future smoking initiation 
and cessation rates have been used in several smoking modeling analyses.50-55,74 The 
model assumes no relapse to smoking among former smokers as is consistent with 
previous models of population smoking48 and aligns with CISNET net annual cessation 
rates where cessation is defined as a successful quit of at least two years with no relapse. 
Individuals exit the model through death or after reaching age 99. Age, gender, and birth 
cohort-specific mortality rates for never smokers, former smokers, and current smokers 
are based on CISNET estimates as well.75,76 
 
To calibrate the smoking sub-model, I adjust each age group’s initiation and cessation 
probabilities by applying scaling factors that modify the initial CISNET estimates. I 
Births 
Never 
smoker 
Current 
smoker 
Deaths 
Former 
smoker 
initiation cessation 
death rate 
Figure 4-1. Smoking sub-model diagram 
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minimized the sum of squared differences between the model and smoking prevalence 
data by age group for both males and females in order to estimate these scaling factors. 
Calibration for this sub-model is necessary because the estimated probabilities were 
developed using the NHIS, whereas the full combined model utilizes data from the 
NSDUH. Differences in their respective survey designs and sample populations, the 
NSDUH has been shown to consistent yields higher smoking prevalence estimates 
compared to the NHIS.77  
Depression sub-model 
In the depression sub-model (Figure 4-2), individuals are born as never depressed and 
may transition to a first onset MD episode based on incidence data from the Baltimore 
Epidemiological Catching Area (ECA) Study,78 the nation’s longest-running psychiatric 
epidemiological cohort study. Because incidence data for females ages<22 and males 
ages <29 do not exist, I estimate the annual probability of a 1st MD episode at younger 
ages as part of calibration using cubic natural splines to fit the sub-model to NSDUH data. 
This sub-model, and the parameterization and calibration approach used for its 
development, has been described in greater detail in Chapter 3. Individuals may recover 
from a 1st MD episode and shift into a formerly depressed category. To address recall 
bias in retrospective assessments of depression,71 I estimated the probability that 
individuals with former depression will underreport their past histories of depressive 
episodes during sub-model calibration. Formerly depressed individuals may also have a 
recurrent MD episode and subsequently recover.79 MD age-specific incidence rates are 
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assumed to remain constant going into the future, as NSDUH data show no visible trends 
in depression patterns by age for the 2005-2015 period.  
 
Comorbidity model 
The combined model of smoking and depression comorbidity includes 15 mutually 
exclusive smoking and depressive states (Figure 4-3) and can project future smoking and 
depression prevalence for the U.S. population ages≥18 from 2015 to 2050. I model males 
and females separately, as females have higher risk for depression and earlier ages at 
onset, while males have higher smoking and mortality rates.80 
Figure 4-2. Depression sub-model diagram 
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Each cohort is born into a never-smoking and never-depressed state at age 0 using 
Census Bureau projected population sizes.81 The model is initialized in the year 1900 with 
the 1900 birth cohort, and new birth cohorts added each year such that by the year 1999, 
the model includes the entire population ages 0-99. Individuals leave the model according 
to smoking and depression-specific mortality rates or after age 99. A relative risk of 
mortality is applied to smoking status-specific mortality rates for individuals with histories 
of depressive episodes. This depression-associated mortality relative risk is estimated 
during model calibration. 
I project future smoking and MD prevalence in the U.S. female and male adult 
populations, assessing baseline trends under a ‘status quo’ scenario. Main outcomes of 
interest are smoking prevalence by depressive state, MD prevalence, and population 
deaths attributable to smoking. Smoking prevalence can be projected by tracking flows 
into the stock of current smokers due to smoking initiation (𝛼), and flows out of this stock 
due to smoking cessation (𝛽) or death (𝜇).48 MD prevalence can similarly be forecasted 
by following inflows due to incidence or recurrence (𝛾) and outflows due to recovery (𝜌) 
or death (𝜇). For example, the number of people with current MD in a given smoking state 
𝑠 at time 𝑡 is calculated accordingly: 
MDa,t,s,g = MDa−1,t−1,s,g × (1 + γa−1,t−1,s,g) × (1 − ρa−1,t−1,s,g) × (1 − μDE,a−1,t−1,s,g) 
Likewise, the number of smokers in a given depressive state 𝑑 at time 𝑡 can be 
determined as follows: 
CSa,t,d,g = CSa−1,t−1,d,g × (1 + αa−1,t−1,d,g) × (1 − βa−1,t−1,d,g) × (1 − μCS,a−1,t−1,d,g) 
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where:  
𝑀𝐷𝑎,𝑡,𝑠,𝑔 = number of individuals with 𝑀𝐷 at age 𝑎 in year 𝑡 in smoking 
state 𝑠 and gender 𝑔 
𝐶𝑆𝑎,𝑡,𝑑,𝑔 = number of current smokers at age 𝑎 in year 𝑡 in depressive state 𝑑 and 
gender 𝑔 
𝑑 = never MD, current MD, or former MD 
𝑠 = never smoker, current smoker, or former smoker 
𝑔 = gender specifying male or female 
 
𝛾𝑎,𝑡,𝑠,𝑔 = incidence or recurrence of 𝑀𝐷 at age 𝑎 in year 𝑡 for smoking state 𝑠 and 
gender 𝑔 
𝜌𝑎,𝑡,𝑠,𝑔 = recovery rate from 𝑀𝐷 at age 𝑎 in year 𝑡 for smoking state 𝑠 and 
gender 𝑔 
𝛼𝑎,𝑡,𝑑,𝑔 = smoking initiation rate at age 𝑎 in year 𝑡 for depressive state 𝑑 and 
gender 𝑔 
𝛽𝑎,𝑡,𝑑,𝑔 = smoking cessation rate at age 𝑎 in year 𝑡 for depressive state 𝑑 and 
gender 𝑔 
𝜇𝑎,𝑡,𝑑,𝑠,𝑔 = death rate at age 𝑎 in year 𝑡 for smoking state 𝑠, depressive state 𝑑, 
and gender 𝑔 
 
With known population sizes and numbers of individuals for each category, smoking and 
MD prevalence can be determined and the number of deaths that occur can be tracked 
over time.  
Model Calibration 
To calibrate the model, I minimized the sum of squared differences between the survey 
and model data with the Davidon-Fletcher-Powell optimization algorithm in the Bhat 
package in R.82 Given initial values and their corresponding upper and lower limits, the 
algorithm searches the parameter space for estimates of scaling factors and interaction 
effects between smoking and depression that enable the model to reproduce smoking 
and depression patterns by age group as observed in the NSDUH from 2005-2015. The 
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initial lower bounds assume that current or former smoker status does not confer health 
advantages with respect to depression onset, recovery or recurrence compared to never 
smokers. The calibration process refines existing parameter estimates and generates 
plausible values that do not otherwise exist in the literature, such as depressive episode 
recovery rates by smoking status. Where possible, initial values as used in the 
optimization were drawn directly from the literature.  
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 Figure 4-3. Smoking and depression model diagram 
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Table 4-2 summarizes input parameters as used in the model, including the smoking and 
depression sub-models. During calibration, I estimated parameters for interaction effects 
including effects that raise the probability of MD onset and recurrence (𝛾) or reduce the 
likelihood of recovery (𝜌) among current or former smokers. I also re-estimated effects of 
depression on smoking behaviors such that those with current depression had increased 
probability of smoking initiation (𝛼) and lower odds of cessation (𝛽). Existing mortality 
estimates for depression control for sociodemographic factors that are not accounted for 
in this population model.11 Therefore I modified death rates (𝜇) by re-estimating the 
relative risk of mortality associated with having a history of depression.  
Table 4-2. Model parameters 
Parameter Source Estimates derived from calibration 
MDE 
incidence 
rates (𝛾)  
- Age at onset of Major Depressive 
Disorder for females ages 22+ and 
males age 29+ in the Baltimore-
ECA cohort study.78 
- Cubic natural splines for MDE 
incidence females ages<22 and 
males ages <29 with knots at 
ages 13 and 18 (See Chapter 3). 
- Probability of DE incidence 
among current and former 
smokers17,83 
MDE 
recurrence 
rates (𝛾) 
- Annual probability of recurrence 
calculated from 45% cumulative 
recurrence after 1st DE over 10 
years in the Baltimore-ECA cohort 
study.79 
- Increased probability of 
recurrence among current 
smokers. 
MDE recovery 
rates (𝜌)  
- Annual probability of recovery 
calculated from 85% cumulative 
recovery from 1st DE over 10 years 
in the Baltimore-ECA cohort 
study.79 
- Recovery rates among current 
and former smokers. 
Smoking 
initiation rates 
(𝛼) 
- Annual CISNET smoking initiation 
probabilities by age, gender, and 
birth cohort.84  
- Increased probability of initiation 
among people with current 
depression.17 
Smoking 
cessation 
rates (𝛽)  
- Annual CISNET smoking cessation 
probabilities by age, gender, and 
birth cohort.84 
- Lower odds of cessation among 
smokers with current 
depression.10 
Death rates by 
smoking 
status (𝜇)  
- All-cause mortality rates by age, 
birth cohort, and gender for never 
smokers, current smokers, and 
former smokers.75 
- Increased mortality risk among 
people with lifetime history of 
depression.11 
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Sensitivity Analysis 
Because parameter uncertainty might have greater influence in dynamic models due to 
nonlinear feedback,85 I conducted sensitivity analyses on the current smoking and 
depression interaction effect estimates derived from calibration to evaluate the sensitivity 
of model outcomes to each of these parameters (See Appendix Table 4-4). I used Latin 
hypercube sampling for parameter space exploration in the pse package in R which 
efficiently samples from across parameter combinations to cover the full range of possible 
model outcomes.86,87 For both the male and female models, 200 parameter combinations 
were sampled from within uniform distributions with minimum and maximum values based 
on the 95% confidence intervals generated during model calibration, or qualitatively 
reasonable values when such intervals failed to be generated. Partial rank correlation 
coefficients were used to evaluate associations between parameters and imprecision for 
three main model outcomes: 1) smoking prevalence among adults with current 
depression, 2) the prevalence ratio between those with current and never depression, 
and 3) the number of smoking-attributable deaths among people with depression.  
Smoking Attributable Mortality 
To assess smoking-attributable mortality, I sum the number of smoking-attributable 
deaths (𝑆𝐴𝐷) for both former smokers and current smokers across all ages and both 
gender using an approach used in previous models.76,88 The total deaths are calculated 
by first multiplying the current and former smoker prevalences (𝑝𝑟𝑒𝑣𝑐𝑠, 𝑓𝑠) by the 
corresponding population sizes (𝑃) for each age group and gender, and then again by the 
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difference in mortality rates between current or former smokers and never smokers 
(𝜇𝑐𝑠,𝑓𝑠,𝑛𝑠) as follows:  
𝑆𝐴𝐷 = ∑ 𝑃 (𝑝𝑟𝑒𝑣𝑐𝑠 × (𝜇𝑐𝑠 − 𝜇𝑛𝑠) + 𝑝𝑟𝑒𝑣𝑓𝑠 ×  (𝜇𝑓𝑠 − 𝜇𝑛𝑠))
𝑎𝑔𝑒,𝑔𝑒𝑛𝑑𝑒𝑟
 
This determines the number of deaths attributable to current and former smoking for a 
given population.  
Results 
The smoking sub-model showed close correspondence with the NSDUH 2005-2015 age-
group specific prevalences for never, current and former smoking following calibration. 
The model initiation and cessation probabilities for males and females are shown in 
Appendix   
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Figure 4-8 and Figure 4-9. CISNET input initiation probabilities were increased for youth 
ages<18 and decreased for adults, while cessation probabilities were generally 
decreased to match model with NSDUH data. 
With calibrated smoking inputs, age-group specific smoking prevalence in the model 
followed the same pattern as observed in the NSDUH data    
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Appendix. Figure 4-10 and Figure 4-11). The model estimates that for women, current 
smoking prevalence decreased from 23.4% in 2005 to 18.9% in 2015, which is consistent 
to the NSDUH decrease from 24.2% (95% CI: 23.1%, 25.3%) to 18.5% (95% CI: 17.8%, 
19.2%). Likewise, for men, the model showed a decrease in total smoking prevalence 
from 29.8% in 2005 to 24.6% in 2015, consistent with  survey data showing a similar 
decline from 30.3% (95% CI: 29.1%, 31.4%) to 24.4% (95% CI: 23.4%, 25.3%).  
The depression sub-model demonstrated good fit with NSDUH data on never (including 
those who fail to recall past episodes), current, and former depression for males and 
females ages 18-64, as shown in Appendix Figure 4-12 and Figure 4-13. Calibrated 
estimates for onset of a first depressive episode and recall error by age are described in 
detail in Chapter 3. The model overestimates current MD prevalence and underestimates 
former MD for the oldest group ages ≥65. When the relative risk of mortality for those with 
a lifetime history of depression was increased, this slightly improved model fit with survey 
data for the oldest age group. No discernible trends in the prevalence of depression were 
observed in either the model or survey data over time.  
For the entire adult population, the depression sub-model estimates were close to their 
corresponding NSDUH prevalence estimates for the 2005-2015 period. Current MD 
prevalence in the model was 8.2% on average for females, compared to 8.4% (95%CI 
8.2%, 8.6%) in the NSDUH. For males, current depression prevalence was 4.7% for this 
period compared to 4.8% (95% CI: 4.7%, 5.0%) based on survey data.  
To calibrate the full model of smoking and depression comorbidity, parameters for both 
sub-models were held constant while interaction effects were adjusted to: 1) increase the 
relative risk of a 1st MD episode among current smokers, 2) decrease the odds of smoking 
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cessation for people with a history of MDE, 3) increase the effects of current depression 
on subsequent smoking initiation, and 4) decrease the likelihood that current smokers 
would recovery from a MD episode. Higher relative risks of mortality applied to those with 
a history of MD were re-estimated for both men and women during calibration. Table 4-3 
shows the adjusted interaction effect estimates. Calibration demonstrated that under 
reasonable parameter bounds, ideal fit was achieved when former smoking status had 
no effect on depression incidence, recovery, or recurrence rates. Furthermore, calibration 
estimates showed that the model performed best when current MD status increased the 
probability of smoking initiation by nearly 3 times compared to those without current MD. 
Table 4-3. Model estimates derived from calibration 
Parameter Description 
Initial 
value 
Lower 
limit 
Upper 
limit 
Estimate 
(Females) 
Estimate 
(Males) 
𝑅𝑅𝑐𝑠_𝑑𝑒𝑝1 
Relative risk of 1st MD 
episode among current 
smokers vs. never 
smokers 
1.70 1 5 1.41 1.06 
𝑅𝑅𝑓𝑠_𝑑𝑒𝑝1 
Relative risk of 1st MD 
episode among former 
smokers vs. never 
smokers 
1.48 1 5 1.00 1.00 
𝑂𝑅ℎ𝑑𝑒𝑝_𝑞𝑢𝑖𝑡 
Odds ratio for smoking 
cessation among 
people with a history of 
MD compared vs. 
never depressed 
0.81 0 1 0.98 0.93 
𝐸𝑓𝑠_𝑑𝑒𝑝𝑟 
Effect of former 
smoking on probability 
of recurrent MD 
episode vs. never 
smoking 
N/A 1 5 1.00 1.00 
𝐸𝑐𝑠_𝑑𝑒𝑝𝑟 
Effect of current 
smoking on probability 
of recurrent MD 
episode vs. never 
smoking 
1.37 1 5 1.00 1.10 
𝐸𝑑𝑒𝑝𝑟_𝑠𝑚𝑘𝑖𝑛𝑖𝑡 
Effect of MD on 
smoking initiation 
1.40 1 5 4.73 2.99 
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𝑑𝑒𝑝𝑟𝑒𝑐𝑜𝑣𝑆𝐹_𝑓𝑠 
Effect of former 
smoking on probability 
of recovering from MD 
episode 
N/A 0 1 1.00 1.00 
𝑑𝑒𝑝𝑟𝑒𝑐𝑜𝑣𝑆𝐹_𝑐𝑠 
Effect of current 
smoking on probability 
of recovering from MD 
episode 
N/A 0 1 0.73 0.75 
𝑅𝑅𝑚𝑑 
Relative risk of 
mortality among people 
with history of MD vs 
never MD11 
1.71 1 10 5.54 2.53 
 
Under a status quo scenario, the model shows that all depressive subgroups experience 
decreasing smoking prevalence over time, with a rising proportion of never smokers in 
each group for females and males (Figure 4-4 and Figure 4-5). Among those in the model 
who have no history of MD, smoking prevalence is projected to decrease for females 
(males) by 45% (37%) between 2016 and 2050 from 17.3% to 9.5% (from 24.2% to 
15.3%). When excluding never MD females (males) in the recall error category, the 
prevalence is 18.0% (males: 24.3%) in 2016 to 9.8% (15.3%) in 2050, also representing 
a 45% (37%) decrease. By comparison, females with current MD have consistently higher 
smoking rates during this period, with 31.2% (males: 36.0%) smoking in 2016, decreasing 
by 38% (31%) to 19.2% (24.8%) prevalence in 2050.  For females (males) who are 
formerly depressed, excluding those with recall error, current smoking prevalence 
decreases from 27.5% (males: 32.7%) to 15.4% (21.4%), representing a 43% (33%) 
decrease. Former smoker prevalence is relatively similar across each subpopulation. 
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Figure 4-4. Smoking projections by depression subgroup, Females ages 18+ 
Never depressed Formerly depressed Currently depressed 
Current 
smoker 
Former 
smoker 
Never 
smoker 
Figure 4-5. Smoking projections by depression subgroup, Males ages 18+ 
Never depressed Formerly depressed Currently depressed 
Current 
smoker 
Former 
smoker 
Never 
smoker 
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The prevalence ratio comparing smoking among adults with current depression with 
adults who have never been depressed is projected by the model to increase over time 
(Figure 4-6). For women, the smoking disparity between those with current and never 
depression increases from 1.73 in 2016 to 1.96 in 2050. For men, the ratio rises from 1.48 
to 1.62. When excluding individuals who fail to report past MDEs from the never 
depressed population, the prevalence ratio is even larger. For the adult female population, 
it rises from 1.80 in 2016 to 2.02 in 2050, such that women with current depression 
projected to be twice as likely to smoke by 2050 compared to women who have never 
been depressed. For men, removed recall error individuals did not change the prevalence 
ratio increase. By 2050, men with depression will be more than 60% more likely to be 
smokers compared to men without a history of depression. 
Figure 4-6. Current-to-never MD smoking prevalence ratio, ages 18+ 
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The model estimates that 642,250 smoking-attributable deaths (SADs) will occur among 
people with current depression from 2016 to 2050 (202,262 deaths among women and 
439,987 deaths among men) (Figure 4-7). The number of annual SADs is expected to 
decline from 22,604 (women: 7,096, men: 15,508) in 2016 to 14,377 by the year 2050 
(women 4,491, men: 9,886). In 2016, smoking-attributable deaths represent 16.4% and 
28.6% of all deaths among women and men with depression. This proportion is 65% and 
33% higher than for women and men without a history of depression, for whom SADs 
represent 9.9% and 21.4% of all population deaths. By 2050, the model estimates that 
SADs will represent 11.4% and 19.7% of all deaths among women and men with 
depression, compared to 7.1% and 14.7% among women and men without a history of 
depression.  
Figure 4-7. Smoking-attributable deaths among adults with MD 
Cumulative number of deaths Proportion of all deaths 
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Partial rank correlation coefficients measuring the linear associations between each 
model outcome and each interaction effect (after removing the effects of other 
parameters) are shown in Appendix Figure 4-14, Figure 4-15, and Figure 4-16. 
Parameters for the relative risk of MD onset among current smokers (𝑅𝑅𝑐𝑠_𝑑𝑒𝑝1), the 
effect of smoking on depression recurrence (𝐸𝑐𝑠_𝑑𝑒𝑝𝑟), and the effect of current MD on 
smoking initiation (𝐸𝑑𝑒𝑝𝑟_𝑠𝑚𝑘𝑖𝑛𝑖𝑡) showed strong positive linear relationships with 
smoking prevalence among adults with depression and the current-to-never MD smoking 
prevalence ratio. Parameters for the odds of cessation among people with any history of 
MD (𝑂𝑅ℎ𝑑𝑒𝑝_𝑞𝑢𝑖𝑡) and the reduced probability of MD recovery among smokers 
(𝑑𝑒𝑝𝑟𝑒𝑐𝑜𝑣𝑆𝐹_𝑐𝑠) showed clear negative linear relationships with these model outcomes. 
These directions of association also held true for smoking and depression interaction 
effects and the number of SADs among adults with depression, but the magnitudes of 
association were slightly more modest. Unlike outcomes for smoking prevalence and 
prevalence ratios, the number of SADs was responsive to changes in the relative risk of 
mortality for people with histories of depression (𝑅𝑅𝑚𝑑). There was a clear negative linear 
relationship between this depression mortality parameter and the number of SADs among 
adults with depression.  
  
 89 
 
Discussion 
This study presents results from the first joint model of smoking and depression 
comorbidity in the U.S. To my knowledge, it is also the first computational model of 
smoking to explicitly model a population with behavioral health comorbidities. The model 
integrates three of the best available data sources on smoking and depression patterns 
in the U.S. First, the underlying sub-model uses re-scaled CISNET age-gender-cohort 
specific smoking initiation and cessation inputs derived from the NHIS 1965-2015. 
Second, depression parameters are taken from the nation’s longest-running psychiatric 
epidemiological survey, the Baltimore Epidemiological Catching Area Follow-up Study 
(See Chapter 3).  I furthermore utilize the NSDUH, the only nationally representative 
dataset with consecutive years of data on depression and smoking for trend assessment.  
I show that under current trends smoking prevalence is projected to decline for people 
with and without MD from 2015-2050. The finding that smoking prevalence is declining 
across the population overall is consistent with that of other simulation models.89 Though 
this is encouraging news in some respects, the model results also demonstrate that in the 
absence of intervention, nearly 600,000 adults with current MD are projected to die 
premature deaths due to smoking from 2018 to 2050. While people with current MD make 
up <7% of the U.S. population, the proportion of tobacco-related deaths in this 
subpopulation is considerably higher (16.4% and 28.6% of all deaths among women and 
men with depression) than for people without a history of MD (9.9% and 21.4% of all 
deaths). 
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The prevalence ratio between those with current MD and with no history of MD is rising, 
indicating that despite the overall decrease in smoking, the smoking disparity by mental 
health status will widen over time. By 2050, women with MD are projected to be twice as 
likely to be smokers compared to women without a history of MD, whereas men with MD 
will be 1.6 times as likely to be smokers. Although the smoking prevalence disparity 
between women with and without MD is greater than for men, the proportion of smoking-
attributable deaths is still larger for men. Accordingly to the model, more than 1 in 4 deaths 
among men with depression and approximately 1 in 6 among women can be attributable 
to smoking annually. In contrast, 1 in 5 and 1 in 10 deaths among men and women who 
have never been depressed can currently be attributed to smoking. It would take until 
2050 for this statistic to be achieved for men and women with current depression. 
Differences in attributable deaths by gender are driven by both the higher prevalence of 
smoking among men and the higher prevalence of depression among women. 
The smoking prevalence estimates reported here are higher than those reported by either 
the NHIS or the NSDUH. Both surveys use definitions of smoking that do not consider 
high probabilities of relapse among recent former smokers. I classify anyone who has 
smoked at all within the past year as current smokers, which includes former smokers 
who quit less than a year ago. For comparison, the NSDUH considers past 30-day 
smokers and the NHIS considers ‘everyday’ or ‘some-day’ cigarette smokers to be current 
smokers. Although this approach translates into higher prevalence estimates, the 
definition avoids considering temporary quitters as former smokers, and simplifies the 
model by avoiding the need to model relapse from quitting. It further improves the model 
fit by aligning my measures for current and former smoking more closely with those used 
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by the CISNET lung consortium in their previously validated models (Shown in Table 
4-1).73,90  
Strengths and limitations 
This model is limited by the relatively few years of survey data available for calibration. 
Thus, larger trends in adult depression prevalence beyond the 11-year period of 
observation may not be captured by the current model. There has been mixed evidence 
about the existence of temporal trends in depression prevalence. Earlier research did not 
find significant trends in depression from 1990 to 2003.91 A recent study using the NSDUH 
data found that depression prevalence has been rising for specific subgroups, including 
youth ages 12-17.92 Nonetheless the NSDUH data in our analysis shows no evidence of 
any increasing or decreasing trends of MD for any adult age-groups. The NSDUH 
depression measures for adolescents differ from that of adults and are not appropriate 
for combined analyses, so it is unclear how changes in youth depression would translate 
into trends for the adult population.93 If rates of depression are increasing over time, the 
results shown here are likely to underestimate the true burden of depression in the 
population, as well as the extent of smoking-attributable mortality among those with 
depression.  
Another limitation of this model is that it does not account for other sociodemographic 
factors associated with both smoking and depression. For example, disparities in smoking 
by depression status are even more prominent when considering differences by 
socioeconomic status.94 The current model does not further disaggregate the population 
beyond age and gender, because introducing too much population heterogeneity can 
dramatically increase the number of unique states in the model, leading to ‘state 
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explosion’.95 It would be problematic to calibrate a model with a large number of states to 
survey data when small numbers in specific subgroups would also lead to unstable 
estimates (e.g. wide confidence intervals). Although existing literature on the dynamics of 
smoking and depression comorbidity generally do not consider additional characteristics 
beyond age and gender, future work, including individual-based or agent-based models, 
could evaluate smoking disparities by mental health status across more diverse 
populations. 
Moreover, the model specification allows for analysis at the population-level, but does not 
examine duration or frequency of depressive episodes at the individual level. The model 
simplifies these aspects of the course of depression. In future work, the model can be 
extended to represent depression at more granular levels.  
The study is also limited by data sources that do not survey the homeless, imprisoned, or 
institutionalized populations, where depression is highly prevalent.96 While absolute 
projections cannot be generalized beyond the civilian, non-institutionalized population, 
the relative trends may still be applicable to other populations. Depression is also known 
to be comorbid with other psychiatric disorders; this analysis does not evaluate 
depression effects independent of other mental disorders. Considering that smoking 
outcomes are worst among those with multiple mental disorders,97 this is an unfortunate 
limitation of the study. If these groups were included, the burden of both smoking and 
depression in the U.S. population, and the smoking disparity by depressive status would 
likely be much larger. 
 93 
 
The lack of comparable data sources beyond the NSDUH that assess both smoking and 
depression prevents validation of this model with other historical data. Comparison of the 
model outputs with real-world data would increase confidence in the results shown here. 
In the absence of such data, the model outputs corroborate existing research showing 
the potential for the burden of tobacco to continue disproportionately affecting people with 
mental illness even as the population experiences declines in smoking prevalence.98-100  
Implications for practice and research 
Despite long-standing recommendations that smoking cessation counseling and services 
be integrated as part of mental health treatment,101-104 only 38% of mental health 
treatment facilities in the U.S. offer tobacco cessation counseling while 25% offer nicotine 
replacement therapy.105 Furthermore, numerous barriers to accessing cessation 
treatments for Medicaid recipients have been documented, even when cessation 
treatment is covered.106 In Chapter 5, I use this model to evaluate the impact of 
hypothetical large-scale cessation interventions that could reduce the burden of tobacco-
related disease and death for people with depression. Future research could also 
evaluate the population-level impact of other interventions that target smokers with 
depression, including the use of smartphone applications, web-based platforms, or 
tailored telephone quitlines.107,108 The use of e-cigarettes among people with mental 
illness has also been rising,109,110 and may offer a less harmful alternative for smokers 
who are unable or unwilling to overcome their nicotine addiction.  
This study demonstrates that unless major changes to the policy and treatment 
environment for smokers with depression are implemented, disparities in smoking and 
smoking-attributable mortality by depression status are projected to persist and widen. 
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The application of simulation models, such as the one presented here, can offer public 
health decision-makers a view of what can be achieved with concerted public health 
action, or what can be expected without it. 
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Appendix 
The NSDUH uses a different definition for smoking than data from CISNET or the NHIS 
that leads to higher overall smoking prevalence estimates. To adjust for this, the annual 
smoking initiation probabilities were calibrated to approximately double the original 
CISNET data for females and males for ages <18. Initiation was scaled to zero for females 
ages ≥18 and males ages ≥35, and to 10% of original CISNET probabilities for males 
ages 18-34. Cessation probabilities were reduced by 21-22% for females ages 18-64, 
and then by 39% for ages≥65. For males, the calibrated sub-model reduced annual 
cessation estimates by 33% for ages 18-34, then by 13% for ages 35-64. Cessation 
probabilities for males ages ≥65 were increased by 13%. 
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Figure 4-8. Smoking initiation probabilities 
 
Female (left) and male (right) annual probabilities of smoking initiation. Data 
shown are for the year 2005. Dots = input data developed by the CISNET lung 
consortium. Lines = model calibrated probabilities.  
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Female (left) and male (right) annual probabilities of smoking cessation. Data 
shown are for the year 2005. Dots = input data developed by the CISNET lung 
consortium. Lines = model calibrated probabilities. 
 
 
Figure 4-9. Smoking cessation probabilities 
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Figure 4-10. Comparison of smoking sub-model and survey data, females ages 18+ 
 
Left panel = never smoker prevalence. Middle panel = current smoker prevalence. Right panel = former smoker 
prevalence. Dots with vertical lines represent point estimates from the 2005-2015 NSDUH and their corresponding 
95% confidence intervals. Lines represent age-group prevalence generated by the calibrated sub-model.  
  
Never smokers Current smokers  Former smokers 
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Figure 4-11. Comparison of smoking sub-model and survey data, males ages 18+ 
 
Left panel = never smoker prevalence. Middle panel = current smoker prevalence. Right panel = former smoker 
prevalence. Dots with vertical lines represent point estimates from the 2005-2015 NSDUH and their corresponding 
95% confidence intervals. Lines represent age-group prevalence generated by the calibrated sub-model.  
 
 
  
Never smokers Current smokers  Former smokers 
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Figure 4-12. Comparison of depression sub-model and survey data, females ages 18+ 
 
Left panel = never depressed prevalence (includes recall error). Middle panel = current depression prevalence. 
Right panel = former depression prevalence. Dots with vertical lines represent point estimates from the 2005-2015 
NSDUH and their corresponding 95% confidence intervals. Lines represent age-group prevalence generated by the 
calibrated sub-model.  
  
Never depressed Currently depressed Formerly depressed 
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Figure 4-13. Comparison of depression sub-model and survey data, males ages 18+ 
 
Left panel = never depressed prevalence (includes recall error). Middle panel = current depression prevalence. 
Right panel = former depression prevalence. Dots with vertical lines represent point estimates from the 2005-2015 
NSDUH and their corresponding 95% confidence intervals. Lines represent age-group prevalence generated by the 
calibrated sub-model.  
  
Never depressed Currently depressed Formerly depressed 
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Table 4-4. Latin hypercube sampling distributions 
*Parameter distributions derived as 95% confidence intervals during model calibration 
Uniform distributions assumed for all parameters. 
 
Parameter Description 
Females Males 
Estimate Min. Max. Estimate Min. Max. 
𝑅𝑅𝑐𝑠_𝑑𝑒𝑝1 
Relative risk of 1st MDE 
among current smokers vs. 
never smokers 
1.41 1.00 2.00 1.06 1.00 2.00 
𝑂𝑅ℎ𝑑𝑒𝑝_𝑞𝑢𝑖𝑡 
Odds ratio for smoking 
cessation among people with 
a history of MDE compared vs. 
never depressed 
0.98 0.50 1.00 0.93 0.50 1.00 
𝐸𝑐𝑠_𝑑𝑒𝑝𝑟 
Effect of current smoking on 
probability of recurrent 
depressive episode vs. never 
smoking 
1.00 1.00 2.00 1.10 1.00 2.00 
𝐸𝑑𝑒𝑝𝑟_𝑠𝑚𝑘𝑖𝑛𝑖𝑡* 
Effect of depression on 
smoking initiation 
4.73 2.36 9.46 2.99 1.55 4.45 
𝑑𝑒𝑝𝑟𝑒𝑐𝑜𝑣𝑆𝐹_𝑐𝑠 
Effect of current smoking on 
probability of recovering from 
depressive episode 
0.73 0.50 1.00 0.75 0.50 1.00 
𝑅𝑅𝑚𝑑* 
Relative risk of mortality 
among people with history of 
MDE vs never MDE 
5.54 3.08 7.98 2.53 1.27 6.21 
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Males Females 
Figure 4-14. Partial rank correlation coefficients: smoking prevalence among adults with MD 
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Smoking prevalence among never depressed adults excludes recall error. 
  
Males Females 
Figure 4-15. Partial rank correlation coefficients: current-to-never MD smoking prevalence ratio 
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Figure 4-16. Partial rank correlation coefficients: smoking-attributable deaths among adults with MD 
Males Females 
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Chapter 5 – Simulating the potential impact of widespread cessation treatment  
for smokers with depression 
 
Background 
Smoking rates in the U.S. have continued to plummet for the general population, but the 
rate of decline has been slower for people with health comorbidities.1 As a result, people 
with mental illness continue to face a disproportionate burden of tobacco-related disease 
and premature death.2,3 In particular, people with major depression (MD) make up 6.7% 
of the adult population,4 but model estimates described in Chapter 4 show that more than 
640,000 smoking-attributable deaths will occur in this group between 2016 and 2050. The 
proportion of all deaths that can be attributed to smoking in the depressed population will 
continue to be greater than for the population without histories of MD even as smoking 
prevalence is projected to decline for the entire population. In the absence of major 
intervention, men and women with MD will become increasingly likely to smoke compared 
to their never depressed counterparts. In sum, the smoking disparity between those with 
and without depression is expected widen.  
The need for effective interventions that reduce the mental illness tobacco use disparity 
is well-documented.5-8 Numerous researchers and national organizations already 
recommend providing smoking cessation counseling and treatments to patients with 
mental illness.6,9-11 Experts have observed that few mental health settings have fully 
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implemented recommendations to integrate smoking cessation treatment with mental 
health care.9,10,12-15 In a 2016 nation-wide assessment, only 37.6% of all public and private 
mental health treatment facilities reported offering cessation counseling, with an even 
smaller proportion (25.2%) offering nicotine replacement therapy.16 Smoking cessation 
significantly reduces depression, while increasing positive affect and quality of life, 
thereby further justifying integrating smoking cessation programs into mental health 
settings.17  
Still, such interventions would not reach the proportion of smokers with depression who 
do not use mental health services at all. Wider use of mental health services could lead 
to further declines in smoking, if health professionals offer cessation treatment for patients 
with depression. A recent study also found that individuals receiving mental health 
treatment in the past year were significantly more likely to have quit smoking compared 
to those who did not receive treatment (37.2% vs. 33.1%, p-value = 0.005), even after 
adjusting for substance use treatment, mental illness severity, and other 
sociodemographic characteristics.1 Increased use of mental health services can then 
improve mental well-being, and in so doing, reduce propensity for smoking.  
The long-term impacts of interventions to address smoking in populations with mental 
illness are challenging to evaluate using traditional research methods. Randomized 
controlled trials are limited by short time frames for follow-up, and are resource and time-
intensive. However, modeling approaches can simulate intervention scenarios that 
cannot be readily tested in the real-world, evaluating their potential impact over time. 
Specifically, systems dynamics models can explore the range of effects of policy levers, 
identifying conditions under which the greatest public health gains can be made.18-21 
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Recent national reports have highlighted the utility of modeling for tobacco control aims.22-
25 Such models can guide macro-level decision-making for policymakers and practitioners 
interested in optimal strategies to address tobacco use disparities.26  
The model described in the previous chapter examines future smoking, depression, and 
mortality outcomes under a status quo scenario that assumes no changes to usual care. 
I now extend this model to evaluate the impact of cessation treatment strategies on 
population health outcomes, including: a) provision of smoking cessation treatment by 
mental health professionals, and b) increased mental health treatment utilization in the 
population of smokers with current MD.  
Methods 
Model overview and extension 
I adapt a previously calibrated system dynamics model of smoking and depression 
comorbidity (Chapter 4) to simulate the impact of cessation interventions targeting 
smokers with current depression in the U.S. A diagram of the model is shown in Figure 
5-1. The population is born into a never smoker and never MD state, based on Census 
Bureau population projections.27 From there, individuals may flow into and out of various 
smoking and depressive states based on annual rates of smoking initiation and cessation, 
or depression incidence, recovery, and recurrence. The base model was calibrated to 
data from the National Survey on Drug Use and Health (NSDUH) 2005-2015, and adjusts 
transition rates to account for interactions between smoking and depression (Chapter 4). 
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Individuals with current MD are those who report at least 5 out of 9 DSM-IV criteria for a 
major depressive episode lasting for a two-week period or longer within the past year 
(Figure 5-1, black compartments). Individuals who are never MD report no lifetime history 
of a major depressive episode (white compartments). Since recall error is common when 
screening for depression,28 I report findings for the never MD population excluding 
individuals who have had past MD but report no lifetime history of it (gray-white diagonal 
hatching pattern). Current smokers are individuals who have smoked at least 100 
cigarettes in their lifetime, and smoked at all within the past year (red outline). 
Smokers with current MD quit based on annual cessation probabilities that are age, 
gender, and birth cohort-specific developed by the Cancer Intervention and Surveillance 
Modeling Network (CISNET) lung consortium with data from the National Health Interview 
Surveys 1965-2015.29 Smokers who talk to health professionals about their depression 
are represented in purple in Figure 5-1.  Their probabilities of quitting (purple dashed 
arrow) are increased when health professionals provide them with cessation treatment. 
I model four hypothetical treatment interventions within the comorbid patient population 
seeking treatment for depression effective in the year 2018, including: A) any cessation 
treatment (including behavioral counseling, pharmacological treatment, or a 
combination), B) any cessation treatment + 10% increase in the proportion of smokers 
seeing health professionals for their depression, C) pharmacological treatment, and D) 
pharmacological treatment + 20% increase in the proportion of smokers seeing health 
professionals for their depression. To cover a wider range of possible joint impact, 
scenario B combines a conservative cessation treatment effect size with a smaller 
increase to mental health service utilization, while scenario D combines a larger treatment 
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effect size with a greater increase to utilization. I evaluate the prevalence ratio between 
those with current and never depression, the proportion of all deaths that are smoking-
attributable, and the number of premature deaths avoided under each of these scenarios. 
All analyses were conducted in R.30 
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MD = Major Depression;  
 
= Smokers who talk to health professionals about their depression;             = Cessation treatment.  
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Figure 5-1. Smoking and depression model extension 
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Mental health treatment utilization 
I operationalize mental health treatment utilization as the proportion of all smokers with 
current MD who reported seeing or talking to a health professional about their depression 
within the past year. Beginning in 2010, the National Survey on Drug Use and Health 
(NSDUH) began asking whether adults saw a health professional for their depression, 
where a health professional includes: a general practitioner or family doctor, other medical 
doctor, psychologist, psychiatrist or psychotherapist, social worker, counselor, other 
mental health professional, nurse, occupational therapist, or other health professional. 
Thus, the sites for professional intervention for depression vary widely. As no visible 
trends were apparent from 2010-2015, I pooled across these years for mental health 
treatment utilization patterns, and applied these estimates to the comorbid population for 
each respective age group and gender, as shown in Figure 5-2. Baseline mental health 
treatment utilization rates were held constant at these proportions through 2050.  
I re-calibrate the model to integrate the extension (Figure 5-1) by minimizing the sum of 
squared differences between the model output and NSDUH estimates of the proportion 
of comorbid people who see health professionals for their depression. I perform this 
minimization with the Davidon-Fletcher-Powell optimization algorithm in the Bhat package 
of R.30,31  Because of the continuous out-flow of individuals from compartments, the final 
treatment seeking rates are effectively lower than the initial values supplied to the model. 
To ensure that the model’s rates match those of survey estimates, I re-estimate the set 
of initial values necessary to accomplish this. Appendix Table 5-2 compares calibrated 
inputs with their final effective proportions. I similarly estimate initial values that translate 
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into 10% and 20% increases in the level of mental health treatment utilization across each 
age group as shown in Appendix Figure 5-7.  
Figure 5-2. Smokers with MD who saw a health professional for their depression 
within the past year, NSDUH 2005-2015 
 
Cessation intervention 
Since smoking cessation interventions vary widely, and are implemented under 
heterogeneous conditions, I rely on estimates from a recent meta-analysis of randomized 
controlled trials that evaluated the effectiveness of cessation interventions for adult 
smokers with current depression across multiple mental health settings.32 The review 
considers interventions tested on people solely with current depression, excluding studies 
of people with a history of depression or with mental health disorders other than 
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depression. Interventions evaluated are psychological and/or pharmacological in nature, 
and are implemented in clinical, primary care, mental health outpatient, home visit, or 
hospital settings.  
Long-term smoking abstinence is evaluated as 7-day point prevalence at the 6- or 12-
month follow-up period. Most studies used biochemical validation (e.g. carbon monoxide 
or cotinine verification) to assess abstinence. Examples of the types of cessation 
interventions evaluated include cognitive behavioral therapy, provision of nicotine gum, 
exercise and counseling, mood management counseling, health education, bupropion 
with counseling and NRT, among others. Because several of the behavioral-based 
cessation interventions failed to translate into significant changes in quitting, this 
moderated the overall combined risk ratio (RR); the meta-analyses showed that the 
probability of cessation increased by 13.7% across 16 interventions combined (RR = 
1.137, 95% CI: 1.001-1.291) relative to comparison condition (no receipt of the cessation 
treatment under evaluation). When analyses were restricted to pharmacological 
interventions only, the RR for long-term abstinence was 1.588 (95% CI: 1.230-2.049) 
compared to placebo condition. These interventions provided patients with varenicline,33 
nicotine gum,34 nicotine replacement therapy,35 bupropion,36 and nicotine patch.37 The 
RRs and their confidence bounds are applied to annual cessation probabilities among 
comorbid smokers who are in contact with health professionals for their depression. 
Premature deaths avoided 
I compare all model outcomes under intervention scenarios with the status quo scenario 
(Chapter 4) in which there are no changes to patterns of mental health treatment 
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utilization or to provision of smoking cessation treatment for people with depression. To 
estimate the greatest possible health gains associated with integrating smoking cessation 
treatment in mental health settings, I assume that at baseline it is not available.  
I evaluate the number of premature deaths avoided under each intervention scenario by 
first summing the total number of smoking-attributable deaths (𝑆𝐴𝐷) among people with 
current depression following the approach described in Chapter 4:23  
𝑆𝐴𝐷 = ∑ 𝑃 (𝑝𝑟𝑒𝑣𝑐𝑠 × (𝜇𝑐𝑠 − 𝜇𝑛𝑠) + 𝑝𝑟𝑒𝑣𝑓𝑠 ×  (𝜇𝑓𝑠 − 𝜇𝑛𝑠))
𝑎𝑔𝑒,𝑔𝑒𝑛𝑑𝑒𝑟
 
I then calculate the difference between this value and that under the status quo to 
determine the number of premature deaths avoided under each intervention scenario. 
Results 
When no changes to mental health treatment utilization patterns are modeled, 52.0% of 
men and 65.9% of women smokers with depression talked to a health professional about 
their depression (Figure 5-2). The model estimates depicted in Figure 5-3 show that if 
these adults received any cessation treatment (red line with 95% CI estimates shown as 
gray ribbons), this would lead to 3,092 total premature deaths avoided (95% CI: 23 to 
6,428) among women and 4,679 premature deaths avoided among men (95% CI: 34 to 
9,753) by the year 2050. The provision of pharmacological treatment would lead to a 
greater number of premature deaths avoided by 2050: 12,472 among women (95% CI: 
5,124 to 20,940) and 18,889 among men (95% CI: 7,778 to 31,643).  
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When cessation treatment is provided in conjunction with increases in the proportion of 
smokers who see health professionals for their depression, some additional health gains 
are achieved. Appendix Figure 5-8 shows that under a baseline scenario, smoking 
prevalence among women decreases by 35.8% (men: 28.7%) from 29.9% (34.8%) in 
2018 to 19.2% (24.8%) in 2050. With any cessation treatment, female (male) smoking 
prevalence decreases by 36.4% (29.1%) over this time period. Any cessation treatment 
considered jointly with a 10% increase in mental health treatment utilization leads to 
36.4% decline for women and 29.2% for men. Figure 5-4 shows that an additional 308 
and 420 female and male premature deaths would be avoided by 2050 with this 10% 
increase (green line). Provision of pharmacological treatment alone leads to 38.2% and 
30.5% decline in female and male smoking prevalence by 2050 (Appendix Figure 5-8). 
Males Females 
Figure 5-3. Cumulative number of premature deaths avoided: 
cessation treatment only 
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When this is paired with a 20% increase in mental health treatment utilization, the model 
estimates a 38.7% and 30.9% decrease in smoking for women and men, with an 
additional 2,458 and 3,688 number of premature deaths avoided (Figure 5-4, purple line). 
 
 
Under the status quo scenario, the smoking prevalence ratio between those with current 
MD and those with never MD (excluding individuals with recall error) increases over the 
2018-2050 period from 1.81 to 2.02 for females and from 1.50 to 1.62 for males (Figure 
5-5). Results where adults with never MD include those with recall error are shown in 
Appendix Figure 5-9. This rising disparity is moderated with more progressive treatment 
intervention scenarios. Under an intervention scenario where any cessation treatment is 
offered with no change to levels of mental health service utilization, this ratio does not 
change. When coupled with a 10% increase in utilization, the prevalence ratios decrease 
Females Males 
Figure 5-4. Cumulative number of premature deaths avoided 
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is again marginal: 1.99 for women and 1.61 for men. With provision of pharmacological 
cessation treatment, the ratio for women reaches 1.93 by 2050, and 1.91 when tied to a 
20% increase in comorbid smokers seeking treatment for their depression. Likewise, for 
men, pharmacological treatment alone would curb the prevalence ratio increase to 1.57 
by 2050 and to 1.56 if combined with a 20% increase in mental health treatment seeking.  
 
With more progressive intervention scenarios also come greater reductions in the 
proportion of deaths attributable to smoking among people with current MD (Figure 5-6). 
In the year 2018, 16.1% and 28.2% of all female and male deaths in the comorbid 
population can be attributed to smoking. By 2050 these proportions are projected to 
decline to 11.4% and 19.7% under a status quo treatment scenario. When smokers who 
Females Males 
Figure 5-5. Current-to-never MD (excludes recall error)  
smoking prevalence ratio 
smoking prevalence ratio 
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see health professionals for their depression receive any cessation treatment, this 
proportion declines to 11.1% for females and 19.5% for males, and only marginally to 
11.1% and 19.4% in conjunction with a 10% increase in mental health treatment 
utilization. Delivery of pharmacological treatment to patients leads to lower smoking-
attributable proportions of all deaths by 2050: 10.5% for females and 18.8% for males. 
The model estimates a modest change to this proportion when pharmacological treatment 
is combined with a 20% increase in utilization: 10.3% for females and 18.6% for males by 
2050. Table 5-1 summarizes all smoking-related outcomes by the year 2050 among the 
adult population with current MD. 
 
  
Females Males 
Figure 5-6. Proportion of deaths attributable to smoking, adults with depression 
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Table 5-1. Model summary of smoking outcomes for adults with major depression by 2050 
 Females Males 
Scenario 
Smoking 
prevalence 
Prevalence 
decrease 
from 2018 
Current-
to-never 
MD  
PR 
% of 
deaths 
attributed 
to 
smoking 
# of 
premature 
deaths 
avoided 
Smoking 
Prevalence 
Prevalence 
decrease 
from 2018 
Current-
to-never 
MD  
PR 
% of 
deaths 
attributed 
to 
smoking 
# of 
premature 
deaths 
avoided 
Baseline ‘status 
quo’ 
19.2% 35.8% 2.02 11.7% 0 24.8% 28.7% 1.62 19.7% 0 
Any cessation Tx 19.0% 36.4% 2.02 11.1% 3,092 24.7% 29.1% 1.62 19.5% 4,679 
Any cessation 
treatment + 10% 
MH Tx increase 
19.0% 36.4% 1.99 11.1% 3,400 24.6% 29.2% 1.61 19.4% 5,099 
Pharmacological 
cessation Tx 
18.5% 38.2% 1.93 10.5% 12,472 24.2% 30.5% 1.57 18.8% 18,889. 
Pharmacological 
cessation Tx + 
20%  MH Tx 
increase 
18.3% 38.7% 1.91 10.3% 14,930 24.0% 30.9% 1.56 18.6% 22,577 
 
PR = prevalence ratio; MH = mental health; Tx = treatment
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Discussion 
This study is the first to evaluate the potential population health benefit of widespread 
smoking cessation treatment for people with a common mental disorder: major 
depression. I develop a simulation model with nationally-representative data to quantify 
a missed public health opportunity for smokers with depression. Under the model 
assumptions, I find that if at the point of care, health professionals provided cessation 
treatment to their patients with depression, 7,771 to 31,361 premature deaths could 
potentially be averted by the year 2050. Doing so would moderately curb the rising 
smoking disparity between those with MD and those with no history of it, and reduce the 
proportion of all deaths that can be attributed to smoking among people with depression.  
The results shown here offer first estimates of the population-level health impact of 
cessation treatment interventions for people with depression given several limitations. 
This model does not account for population heterogeneity and the complex treatment 
needs of people with multiple behavioral health conditions. Cessation treatment options 
vary widely across healthcare contexts and need to be adapted for the setting (inpatient 
vs. outpatient) and the patients, especially those with other co-occurring psychiatric 
disorders. Smokers with serious mental illness may have complicated healthcare profiles 
that differ considerably from patients included in randomized controlled trials. This study 
does not further disaggregate the population by other sociodemographic characteristics 
such as socioeconomic status. Research shows that disparities in smoking by depression 
status are even more pronounced when taking level of education and income into 
account.38 
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Another limitation is that the randomized controlled trials on which the treatment effect 
estimates are based may not be generalizable to smokers with depression in real-world 
settings. For example, while one trial did not require a desire to quit for participation,11 
another recruited patients from smoking cessation clinics who were already motivated to 
quit.33 The meta-analysis risk ratios were based on evaluations of the efficacy of different 
cessation treatment interventions.32 Efficacy studies generally overestimate the true ‘real-
world’ effectiveness of interventions, and the extent to which they can be generalized 
outside the context of a clinical trial.39,40 On the other hand, the true effects of cessation 
interventions included in the meta-analysis may be underestimated because of the 
inclusion of interventions that failed to translate into significant improvements in smoking 
abstinence, as well as the use control arm conditions that generally exceeded standard 
care (e.g. including behavioral smoking cessation counseling in both the intervention and 
control arm34,35,37).  
The modeling assumptions used in this study are generous. The analysis assumes that 
all depressed patients seeking mental health services are interested in quitting smoking. 
Although research has demonstrated that many adults with depression want to quit 
smoking,41 others may be reluctant to quit based on the erroneous belief that doing so 
could worsen their mental health42 or unwilling to quit altogether. Secondly, I assume that 
their providers universally offer them cessation treatment. Health professionals are 
commonly under the misconception that smoking can interfere with patients’ mental 
health recovery, despite evidence indicating that cessation confers mental health benefits 
including reducing depressive symptoms.43-47 Surveys show that mental health 
professionals believe that their patients have other immediate problems to address, hold 
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permissive attitudes towards their patient’s continued smoking, and of greater concern, 
health providers commonly believe their patients with mental illness are not interested in 
quitting.48 Furthermore, qualitative research indicates that health providers are not 
perceived as sources of smoking cessation support by people with severe mental 
illness,49 though this may be less applicable to people with common mental health 
disorders like depression. 
I furthermore simulate optimistic scenarios with improved access to and utilization of 
mental health services. Despite passage of the Mental Health Parity and Addiction Equity 
Act, the level of insurance coverage for mental health care varies, with a significant 
proportion of behavioral care needs addressed out-of-network with high out-of-pocket 
costs.50 Mental health service uptake is hindered by the well-documented stigma 
surrounding the use of treatment.51 Although women have higher rates of depression than 
men, men stand to benefit the most from such interventions given both their higher 
smoking prevalence and lower utilization of mental health services compared to women.  
Finally, the status quo scenario assumes little to no integration of cessation treatment in 
mental health services at baseline which inflates the overall health gain estimates. The 
level of smoking cessation treatment integration has very likely increased since the 
Affordable Care Act (ACA) was implemented. More than a third of mental health facilities 
report offering cessation help to patients, and while it is unclear how this translates into 
patient utilization at the individual level,52 these improvements mean progress towards 
achieving the public health gains estimated by this study is already taking place 
Policy implications 
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Public health leaders and professional organizations have long called for the integration 
of smoking cessation treatment into standard care for patients with mental illness.5-
7,9,10,14,53 Yet barriers to the widespread use of cessation treatment, even in general health 
settings, persist. The ACA greatly increased coverage for tobacco cessation treatment in 
private health insurance plans and under Medicaid. Tobacco treatment coverage is now 
required for non-grandfathered private health marketplace plans, as well as some newly 
eligible beneficiaries in states with Medicaid expansions. Policies that mandate coverage 
of tobacco dependence treatment in private insurance plans can still fail to translate into 
actual patient utilization of such services. Some private insurance plans only provide 
access to treatment for patients who meet medically necessary prerequisites; others do 
not make it clear to patients that this is a covered benefit.3,54  
The Medicaid population has much higher smoking rates and higher levels of 
psychological distress compared to people with private insurance or other coverage.55 
When coupled with high utilization rates, Medicaid coverage of cessation treatment can 
significantly reduce population smoking.56 States that elected to expand Medicaid 
experienced increases in quitting among low-income adults.57 While Medicaid expansion 
plans cover tobacco cessation treatment without cost-sharing, they may still impose cost-
sharing and limits on the number of quit attempts per year, or require counseling and prior 
authorization to receive cessation medications.58,59 Under traditional Medicaid plans, 
cessation benefits must be covered for pregnant women, but are not required to do so for 
all enrollees. As a result, there is wide variation in state Medicaid programs’ coverage 
and promotion of cessation medications.60,61 In a qualitative study examining low 
utilization rates among Medicaid recipients in Kansas, barriers described included failure 
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of physicians to prescribe treatments and a lack of patient awareness of treatment 
coverage.62 It is unclear what incentives exist to encourage physicians to prescribe 
cessation treatments, as Medicaid coverage is generally based on capitated payments.  
The ability of enrollees to access cessation treatment coverage is also at risk as more 
states are adding Medicaid work requirements.63 Smokers and people with mental illness 
make up a disproportionate share of Medicaid enrollees55 and continue to encounter 
barriers to treatment access despite recent policy reforms. 
While there is clear value in broad system-wide interventions to help people with 
depression quit smoking, the health gains associated with widespread delivery of 
cessation treatment specifically in mental health settings might be modest. The model 
shows that under the most highly optimistic treatment scenario evaluated, less than 5% 
of the 597,255 premature smoking-attributable deaths among adults with depression 
during the 2018-2050 period would be averted. These results should not dissuade 
decision-makers from actively promoting smoking cessation treatments, which are known 
to be highly cost-effective, including for people with depression and other psychiatric 
conditions.64-66 However given the investment required to provide them comprehensively, 
including the costs of broadening access to mental health services, provision of cessation 
treatment in mental health settings should be pursued in conjunction with other 
approaches. 
Tobacco control strategies outside of the clinical setting can reduce smoking in 
populations with mental illness. Smoking cessation telephone quitlines are effective at 
helping smokers quit, especially when tailored for those with mental health conditions. In 
a recent randomized control trial, a specialized quitline designed for patients with mental 
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health conditions increased the likelihood of quitting compared to use of a standard 
quitline.67 Smoke-free air laws implemented in restaurants and bars have been shown to 
reduce smoking for people with some specific psychiatric conditions.68 Suggestive 
evidence also indicates that people with mental disorders are also sensitive to changes 
in price,69 and would therefore be responsive to increases in tobacco taxes. Other 
research suggests that e-cigarettes may be just as effective at helping smokers with 
mental illness quit as nicotine replacement therapy,70 although whether they can serve 
as cessation aids remains a topic of strong debate.71,72 If e-cigarettes or other novel 
nicotine delivery products can deliver on their promise of harm reduction, strategies to 
promote their use among smokers with mental illness who would otherwise not quit may 
be worth pursuing.  
Notably, the Food and Drug Administration recently announced its intention to explore 
regulations that would reduce the level of nicotine in cigarettes to non-addictive levels, 
using a simulation model to evaluate the potential public health benefits of doing so.73,74 
This regulation would undoubtedly have enormous impact on the lives of people with 
mental illness. Randomized controlled trials are now being conducted to evaluate the 
impact of very low nicotine cigarettes on the smoking behavior of people with comorbid 
mood and/or anxiety disorders.75 Early evidence from a clinical trial showed that smokers 
with depressive symptoms are equally responsive to changes in the level of nicotine in 
their cigarettes as smokers without depressive symptoms.76  
In sum, far more aggressive strategies are needed to markedly reduce tobacco-related 
disease and death for people with depression, and to achieve these reductions in fewer 
years. This should include efforts to prevent smoking initiation among youth and youth 
 134 
 
adults with depressive symptoms. As people with mental illness are increasingly 
represented in the country’s remaining smoking population,77 tobacco control and mental 
health advocates are now confronted with the important challenge of improving the policy 
and treatment environment for comorbid smokers. The task ahead is enormous and it 
may require new and innovative strategies beyond those evaluated here.  
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Appendix 
Table 5-2. Proportion of smokers seeing health professionals for depression 
Males Baseline distribution 10% proportional increase 20% proportional increase 
Age group Calibrated input Final Calibrated input Final Calibrated input Final 
18 to 25 57.0% 37.0% 63.3% 40.6% 69.7% 44.3% 
26 to 34 49.6% 45.9% 50.5% 50.5% 55.8% 55.1% 
35 to 49 55.2% 53.9% 62.6% 59.3% 70.0% 64.7% 
50 to 64 75.7% 68.0% 83.2% 74.8% 90.6% 81.6% 
65+ 42.8% 55.2% 43.1% 60.7% 47.0% 66.2% 
       
Females Baseline 10% increase 20% increase 
Age group Calibrated input Final Calibrated input Final Calibrated input Final 
18 to 25 63.8% 50.1% 70.1% 55.1% 76.5% 60.1% 
26 to 34 71.1% 61.4% 78.2% 67.6% 85.3% 73.7% 
35 to 49 73.7% 70.3% 81.1% 77.4% 88.5% 84.4% 
50 to 64 74.8% 73.9% 82.3% 81.3% 89.7% 88.7% 
65+ 72.6% 73.6% 79.9% 81.0% 87.2% 88.3% 
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Bars represent the percent of smokers with a past year major depressive episode (MDE) 
for the NSDUH 2010-2015 period who reported that they “saw a health professional for 
their MDE within the past year.” Vertical black lines are the corresponding 95% 
confidence intervals. Teal line = final distribution following calibration to NSDUH 
estimates. Green line = final calibrated values assuming a 10% increase in utilization. 
Purple line = final calibrated values assuming a 20% increase in utilization. 
Figure 5-7. Mental health treatment utilization among smokers with depression 
Females Males 
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Figure 5-8. Smoking prevalence among adults with depression 
Females Males 
Females Males 
Figure 5-9. Current-to-never depression (includes recall error)  
smoking prevalence ratio 
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Chapter 6 – Conclusion 
 
 
“When life gives you a wake-up call, answer it.” – Rebecca, former smoker1 
 
  
Faced with the debilitating health consequences of her smoking, Rebecca was finally able 
to quit after 36 years as a smoker, and she has since offered this advice to countless 
smokers across the country. Public health agencies are now also waking up to the crisis 
of smoking among people with mental illness: Rebecca’s inclusion in the CDC’s Tips from 
Former Smokers campaign marks the first time that a national tobacco education 
campaign has specifically targeted smokers with mental health conditions. What was 
once described as a hidden epidemic,2 is now receiving national attention as strategic 
partnerships are forming around the issue.3 In October 2016, the American Cancer 
Society and the Smoking Cessation Leadership Center convened more than 16 leading 
organizations in Atlanta with the ambitious shared goal of driving down smoking rates in 
populations with mental illness.4 These recent partnerships between major organizations 
offer promising opportunities for large-scale change.3,5 Researchers have increasingly 
turned their focus to this tobacco use disparity as well. The literature on smoking and 
mental illness has grown significantly in the last two decades, improving our 
understanding of and ability to address this particular tobacco burden.6  
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The work presented here is part of that larger undertaking. We now know that smoking is 
the primary driver of differences in life expectancy between those with and without serious 
mental illness (Chapter 2). I found that while smokers with serious psychological distress 
(SPD) lose roughly 15 years of life expectancy at age 40, never smokers with SPD only 
lose 5. Adults with SPD who quit smoking live 5-6 years longer than those who continue. 
Prior to this study, estimates of the reduced lifespan of people with mental illness failed 
to disentangle the mortality risk associated with psychological distress from that produced 
by smoking.  
Next, I modeled the epidemiology of depression—a necessary precondition to modeling 
its comorbidity with smoking—and discovered that current estimates of the lifetime burden 
of depression in the U.S. are inaccurate (Chapter 3). Over 40% of adults likely fail to 
report a past depressive episode. National cross-sectional data and modeling analyses 
suggest that lifetime experience with major depressive episodes are nearly twice the 
reported rate for women (15.6% vs. 28.7%) and almost 70% higher than the estimate for 
men (9.5% vs. 16.0%). The experience of depression is far more common than what 
available survey data indicate, a sign that estimates of its lower prevalence should be met 
with skepticism, and that efforts to improve the mental health of the nation must be 
redoubled.  
Using this as an underlying sub-model, I turned to the development of a system dynamics 
model of the relationship between smoking and depression (Chapter 4). The vicious cycle 
that Rebecca and other depressed smokers find themselves in has major implications at 
the population level. In the absence of large-scale strategies that address disparate 
smoking rates between those with depression and those without a history of it, the gap is 
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projected to widen over the next several decades. By then women with depression will be 
twice as likely to smoke as they are now. Men with depression will be 1.6 times as likely 
to smoke. Adults with major depression only make up 6.7% of the population,7 but from 
2016 to 2050, more than 640,000 smoking-attributable deaths are expected to occur in 
this group. 
Finally, I simulated the potential health gains associated with aggressive smoking 
cessation treatment for people with depression (Chapter 5). Research has shown that 
both pharmacological and general cessation interventions are effective at helping patients 
with depression quit.8 If starting in 2018 every adult smoker seeing a mental health 
professional for their depression received cessation treatment, thousands of premature 
deaths could be avoided, the tobacco use disparity between those with and without 
depression would narrow, and the proportion of deaths among people with depression 
that are smoking-related would decline. However, this would only represent 
approximately 5% of the nearly 600,000 smoking-attributable deaths that would occur in 
this population between 2018 and 2050. 
Future work 
These findings prompt further questions. Thus far I have examined mortality outcomes, 
yet both smoking and depression are leading contributors to disability. Future modeling 
efforts could measure the extent to which interventions alleviate the disability burden from 
comorbid smokers. What impact would smoking and depression comorbidity have on 
other health metrics, such as disability-adjusted life years? Even if the health gains 
associated with providing cessation treatment in mental health settings are modest, other 
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benefits including improved quality of life and increased productivity have yet to be 
quantified. Although these studies provide estimates of the impact of interventions on 
smoking outcomes, additional work could evaluate the effects of such interventions on 
depression outcomes, given the dynamic relationship between smoking and 
depression.9,10 How might cessation treatment influence mental health outcomes? How 
might mental health interventions influence smoking outcomes? What would be the 
associated costs? 
The model I developed can be refined to assess more specific healthcare environments 
including mental health outpatient and primary care settings. Outside of the U.S., many 
high-income countries have health care systems better equipped for the widespread 
delivery of mental health services and smoking cessation medications. What are the 
projected population health outcomes in these other contexts?  
Future research could explore the potential impact of other types of cessation 
interventions. Effective strategies need not take place in a health care context. New 
smartphone applications or web-based platforms could facilitate smoking cessation but 
have not been evaluated with smokers who have mental illness.11 Telephone quitlines 
when tailored for people with mental health conditions have been shown to be more 
effective than standard smoking cessation quitlines.12  
To date, there is limited research evaluating the costs and benefits of different tobacco 
control interventions for people with mental illness. Decision-makers and organizations 
committed to reducing the toll of smoking on communities with behavioral health 
comorbidities need evidence comparing potential health interventions with each other. 
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Research in this area could help public health leaders determine how resources 
dedicated to this issue are allocated—this includes information that assesses the 
opportunity costs associated with pursuing one approach over another. Simulation 
modeling methods can be used to evaluate and compare the impact of interventions, 
forecasting both health and economic outcomes in the near and distant future.13-16 Other 
large-scale tobacco control strategies may confer larger health benefits than providing 
cessation treatment to smokers with mental illness. 
Modeling methods could prove useful in evaluating tobacco harm reduction strategies for 
smokers with mental illness in particular. E-cigarette use has been rising not just in the 
general population, but also among smokers with mental illness.17 Smokers with mental 
health conditions are just as or more likely to use e-cigarettes than smokers without.18 
Smokers who are unable to quit, but wish to cut back the number of cigarettes they are 
smoking or substitute their cigarettes completely, may turn to e-cigarettes. Though still 
controversial,19 how might patterns of e-cigarette use (or other novel nicotine delivery 
products) among people with mental disorders shape the tobacco use disparity? If such 
devices are equally effective at helping smokers with mental illness quit compared to 
typical cessation treatments, as some research indicates,20 then their widespread 
availability to consumers would facilitate uptake among those unable or unwilling to 
abstain from nicotine altogether.  
Should the Food and Drug Administration follow through on its plans reduce nicotine in 
cigarettes to non-addictive levels, the impact of such broad-scale regulations on smokers 
with mental illness are important.21,22 The model I developed could be applied to evaluate 
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the population-level impact of a nicotine reduction strategy for smokers with depression 
and tobacco use disparities by mental health status.  
Other studies could evaluate innovative interventions that prevent smoking initiation 
among young people with symptoms of depression, or consider uptake of e-cigarettes 
among people with mental illness as a means of quitting. Smoking and depression are 
social processes driven in part by spillover or social network influences.23,24 Other models 
could explicitly simulate the impact of interventions on communities where networks of 
smokers with mental illness may cluster.  
A great deal of the existing research focuses on helping smokers with mental illness quit 
smoking, whereas little addresses preventing young people with behavioral health 
conditions from starting to smoke. Just as tobacco cessation and mental health treatment 
should be integrated, so too should tobacco prevention and mental health promotion 
strategies. Like smoking, depression also has its onset during adolescence and young 
adulthood (see Chapter 3). The feedback cycle between smoking and depressive 
symptoms suggests that early smoking prevention could lead to even greater mental 
health gains in the long-run. 
In pursuing these new research questions, it is important to recognize that the 
effectiveness of intervention strategies will differ by type of mental disorder diagnosis, 
degree of severity, and level of baseline interest in quitting. The smoking patterns of 
people with depression may be more similar to the general population than to people with 
schizophrenia, for example. Not all smokers with mental illness will be interested in 
quitting, and researchers should consider every stage of their quitting process: from 
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motivating the smoker to make a quit attempt, to the quit attempt itself, to relapse 
prevention.25  
This body of work puts forth the argument that the time to view smoking and mental health 
as separate public health issues is over. Together they represent a complex system 
capable of generating better or worse health outcomes, smaller or larger disparities, 
depending on how quickly we take action. Research now shows that in the next three 
decades, hundreds of thousands of people with depression could die early deaths from 
smoking. It is time to answer the call.   
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